Streamline Health Solutions (STRM) 10-K 22 Apr 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jan. 31, 2019	Mar. 24, 2019	Jul. 31, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	STREAMLINE HEALTH SOLUTIONS INC.
Entity Central Index Key	0001008586
Document Type	10-K
Document Period End Date	Jan. 31, 2019
Amendment Flag	false
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--01-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 20,232,964
Entity Common Stock, Shares Outstanding		20,905,691

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jan. 31, 2019	Jan. 31, 2018
Current assets:
Cash and cash equivalents	$ 2,376,000	$ 4,620,000
Accounts receivable, net of allowance for doubtful accounts of $345,000 and $349,000, respectively	2,933,000	3,001,000
Contract receivables	1,263,000	224,000
Prepaid assets	901,000	1,255,000
Other current assets	445,000	547,000
Total current assets	7,918,000	9,647,000
Property and equipment:
Accumulated depreciation and amortization	(1,516,000)	(3,835,000)
Property and equipment, net of accumulated amortization of $1,516,000 and $3,835,000, respectively	237,000	1,162,000
Contract receivables, less current portion	407,000
Capitalized software development costs, net of accumulated amortization of $19,689,000 and $18,658,000, respectively	5,698,000	4,308,000
Intangible assets, net of accumulated amortization of $3,538,000 and $6,969,000, respectively	1,669,000	5,835,000
Goodwill	15,537,000	15,537,000
Other	274,000	642,000
Total non-current assets	23,822,000	27,484,000
Total assets	31,740,000	37,131,000
Current liabilities:
Accounts payable	1,280,000	421,000
Accrued compensation	789,000	342,000
Accrued other expenses	1,025,000	610,000
Current portion of term loan	597,000	597,000
Deferred revenues	8,338,000	9,482,000
Other	94,000
Total current liabilities	12,123,000	11,452,000
Non-current liabilities:
Term loan, net of current portion and deferred financing cost of $82,000 and $128,000, respectively	3,351,000	3,901,000
Royalty liability	905,000	2,469,000
Deferred revenues, less current portion	432,000	333,000
Other	41,000	274,000
Total non-current liabilities	4,729,000	6,977,000
Total liabilities	16,852,000	18,429,000
Series A 0% Convertible Redeemable Preferred Stock, $.01 par value per share, $8,686,000 and $8,850,000 redemption value, 4,000,000 shares authorized, 2,895,464 and 2,949,995 shares issued and outstanding, respectively	8,686,000	8,850,000
Stockholders’ equity:
Common stock, $.01 par value per share, 45,000,000 shares authorized; 20,767,708 and 20,005,977 shares issued and outstanding, respectively	208,000	200,000
Additional paid in capital	82,544,000	81,777,000
Accumulated deficit	(76,550,000)	(72,125,000)
Total stockholders’ equity	6,202,000	9,852,000
Total liability and stockholders' equity	$ 31,740,000	$ 37,131,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Allowance for doubtful accounts	$ 345,000	$ 349,000
Accumulated amortization of property and equipment	1,516,000	3,835,000
Accumulated amortization of capitalized software development costs	19,689,000	18,658,000
Accumulated amortization of intangible assets	3,858,000	6,969,000
Deferred financing costs, accumulated amortization	$ 82,000	$ 128,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	45,000,000	45,000,000
Common stock, shares issued (in shares)	20,767,708	20,005,977
Common stock, shares outstanding (in shares)	20,767,708	20,005,977
Series A Preferred Stock
Preferred stock dividend rate (as a percent)	0.00%	0.00%
Convertible redeemable preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Convertible redeemable preferred stock, redemption value	$ 8,686,000	$ 8,850,000
Convertible redeemable preferred stock, shares authorized (in shares)	4,000,000	4,000,000
Convertible redeemable preferred stock, shares issued (in shares)	2,895,464	2,949,995
Convertible redeemable preferred stock, shares outstanding (in shares)	2,895,464	2,949,995

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Revenues:
Professional services	$ 1,336,000	$ 2,744,000
Audit services	1,118,000	1,216,000
Software as a service	4,853,000	5,864,000
Total revenues	22,365,000	24,338,000
Operating expenses:
Cost of professional services	2,657,000	2,401,000
Cost of audit services	1,373,000	1,604,000
Cost of software as a service	992,000	1,319,000
Selling, general and administrative	10,554,000	11,434,000
Research and development	4,261,000	5,352,000
Impairment of long-lived assets	3,681,000
Loss on exit of operating lease	1,034,000
Total operating expenses	27,667,000	26,960,000
Operating loss	(5,302,000)	(2,622,000)
Other income (expense):
Interest expense	(384,000)	(474,000)
Miscellaneous (expense) income	(179,000)	(87,000)
Loss before income taxes	(5,865,000)	(3,183,000)
Income tax benefit		84,000
Net loss	$ (5,865,000)	$ (3,099,000)
Net loss per common share - basic (in dollars per share)	$ (0.30)	$ (0.16)
Weighted average number of common shares - basic (in shares)	19,540,980	19,090,899
Net loss per common share - diluted (in dollars per share)	$ (0.30)	$ (0.16)
Weighted average number of common shares - diluted (in shares)	19,540,980	19,090,899
System Sales
Revenues:
Revenues	$ 2,472,000	$ 1,343,000
Operating expenses:
Cost of goods and services sold	942,000	1,946,000
Maintenance and Support
Revenues:
Revenues	12,586,000	13,171,000
Operating expenses:
Cost of goods and services sold	$ 2,173,000	$ 2,904,000

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Common Stock	Additional Paid-in Capital	Retained Earnings	Total
Beginning balance (in shares) at Jan. 31, 2017	19,695,391
Beginning balance at Jan. 31, 2017	$ 197,000	$ 80,668,000	$ (69,026,000)	$ 11,839,000
Statement of Changes in stockholders' equity
Stock issued pursuant to Employee Stock Purchase Plan		45,000		45,000
Stock issued pursuant to Employee Stock Purchase Plan (in shares)	47,282
Restricted stock issued	$ 3,000	(3,000)
Restricted stock issued (in shares)	295,337
Surrender of stock upon vesting of restricted stock to satisfy tax withholding obligations (in shares)	(32,033)
Surrender of stock upon vesting of restricted stock to satisfy tax withholding obligations		(42,000)		(42,000)
Share-based compensation expense		1,109,000		1,109,000
Net loss			(3,099,000)	(3,099,000)
Ending balance (in shares) at Jan. 31, 2018	20,005,977
Ending balance at Jan. 31, 2018	$ 200,000	81,777,000	(72,125,000)	9,852,000
Statement of Changes in stockholders' equity
Stock issued pursuant to Employee Stock Purchase Plan and exercise of stock options		44,000		44,000
Stock issued pursuant to Employee Stock Purchase Plan and exercise of stock options (in shares)	48,616
Restricted stock issued	$ 8,000	(8,000)
Restricted stock issued (in shares)	826,666
Restricted stock forfeited	$ (1,000)	1,000
Restricted stock forfeited (in shares)	(130,833)
Surrender of stock upon vesting of restricted stock to satisfy tax withholding obligations (in shares)	(37,249)
Surrender of stock upon vesting of restricted stock to satisfy tax withholding obligations		(62,000)		(62,000)
Conversion of Series A Preferred Stock	$ 1,000	163,000		164,000
Conversion of Series A Preferred Stock (in shares)	54,531
Share-based compensation expense		629,000		629,000
Net loss			(5,865,000)	(5,865,000)
Ending balance (in shares) at Jan. 31, 2019	20,767,708
Ending balance at Jan. 31, 2019	$ 208,000	$ 82,544,000	(76,550,000)	6,202,000
Statement of Changes in stockholders' equity
Cumulative effect of ASC 606 implementation			$ 1,440,000	$ 1,440,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Cash flows from operating activities:
Net loss	$ (5,865,000)	$ (3,099,000)
Adjustments to reconcile net loss to net cash provided by operating activities, net of effect of acquisitions:
Depreciation	450,000	774,000
Amortization of capitalized software development costs	1,160,000	2,113,000
Amortization of intangible assets	937,000	1,161,000
Amortization of other deferred costs	415,000	341,000
Valuation adjustment	126,000	95,000
Impairment of long-lived assets	3,681,000
Loss on exit of operating lease	1,034,000
Loss (gain) on disposal of fixed assets	7,000	(16,000)
Share-based compensation expense	629,000	1,109,000
Provision for accounts receivable	13,000	234,000
Changes in assets and liabilities, net of assets acquired:
Accounts and contract receivables	(640,000)	1,498,000
Other assets	466,000	(696,000)
Accounts payable	859,000	(695,000)
Accrued expenses	129,000	(117,000)
Deferred revenues	(2,004,000)	(671,000)
Net cash provided by operating activities	1,397,000	2,031,000
Cash flows from investing activities:
Purchases of property and equipment	(21,000)	(49,000)
Proceeds from sales of property and equipment	21,000	20,000
Capitalization of software development costs	(3,003,000)	(1,836,000)
Net cash used in investing activities	(3,003,000)	(1,865,000)
Cash flows from financing activities:
Principal repayments on term loans	(597,000)	(1,112,000)
Principal payments on capital lease obligations		(91,000)
Payments related to settlement of employee shared-based awards	(62,000)	(42,000)
Proceeds from exercise of stock options and stock purchase plan	44,000	45,000
Payment of deferred financing costs	(23,000)
Net cash used in financing activities	(638,000)	(1,200,000)
Net decrease in cash and cash equivalents	(2,244,000)	(1,034,000)
Cash and cash equivalents at beginning of year	4,620,000	5,654,000
Cash and cash equivalents at end of year	2,376,000	4,620,000
Supplemental cash flow disclosures:
Interest paid	417,000	418,000
Income taxes paid	11,000	$ 8,000
Supplemental disclosure of non-cash financing activities:
Conversion of Series A Preferred Stock to common shares	$ 164,000
Conversion of Series A Preferred Stock to common shares (in shares)	54,531
Modification of royalty liability associated with the acquisition of Clinical Analytics	$ 1,644,000

Organization and Description of

Organization and Description of Business	12 Months Ended
	Jan. 31, 2019
Organization and Description of Business
ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1 — ORGANIZATION AND DESCRIPTION OF BUSINESS Streamline Health Solutions, Inc. and its subsidiary (“we”, “us”, “our”, “Streamline”, or the “Company”) operates in one segment as a provider of healthcare information technology solutions and associated services. The Company provides these capabilities through the licensing of its HIM, Coding & CDI, eValuator Coding Analysis Platform, Financial Management and Patient Care solutions and other workflow software applications and the use of such applications by software as a service (“SaaS”). The Company also provides audit services to help clients optimize their internal clinical documentation and coding functions, as well as implementation and consulting services to complement its software solutions. The Company’s software and services enable hospitals and integrated healthcare delivery systems in the United States and Canada to capture, store, manage, route, retrieve and process patient clinical, financial and other healthcare provider information related to the patient revenue cycle. Fiscal Year All references to a fiscal year refer to the fiscal year commencing February 1 in that calendar year and ending on January 31 of the following calendar year.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Jan. 31, 2019
Significant Accounting Policies
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The consolidated financial statements include the accounts of Streamline Health Solutions, Inc. and its wholly-owned subsidiary, Streamline Health, Inc. All significant intercompany transactions and balances are eliminated in consolidation. All amounts in the consolidated financial statements, notes and tables have been rounded to the nearest thousand dollars, except share and per share amounts, unless otherwise indicated. Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates and judgments, including those related to stock-based compensation, capitalization of software development costs, intangible assets, allowance for doubtful accounts, and income taxes. Actual results could differ from those estimates. Cash and Cash Equivalents Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash demand deposits. Cash deposits are placed in Federal Deposit Insurance Corporation (“FDIC”) insured financial institutions. Cash deposits may exceed FDIC insured levels from time to time. For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly-liquid investments purchased with an original maturity of three months or less to be cash equivalents. Receivables Accounts and contract receivables are comprised of amounts owed to the Company for licensed software, professional services, including coding audit, maintenance services, and software as a service and are presented net of the allowance for doubtful accounts. The timing of revenue recognition may not coincide with the billing terms of the client contract, resulting in unbilled receivables or deferred revenues; therefore certain contract receivables represent revenues recognized prior to client billings. Individual contract terms with clients or resellers determine when receivables are due. For billings where the criteria for revenue recognition have not been met, deferred revenue is recorded until all revenue recognition criteria have been met. Allowance for Doubtful Accounts In determining the allowance for doubtful accounts, aged receivables are analyzed periodically by management. Each identified receivable is reviewed based upon the most recent information available and the status of any open or unresolved issues with the client preventing the payment thereof. Corrective action, if necessary, is taken by the Company to resolve open issues related to unpaid receivables. During these periodic reviews, the Company determines the required allowances for doubtful accounts for estimated losses resulting from the unwillingness or inability of its clients or resellers to make required payments. The allowance for doubtful accounts was approximately $345,000 and $349,000 at January 31, 2019 and 2018, respectively. The Company believes that its reserve is adequate, however results may differ in future periods. Bad debt expense for fiscal years 2018 and 2017 was as follows: 2018 2017 Bad debt expense $ 13,000 $ 234,000 Concessions Accrual In determining the concessions accrual, the Company evaluates historical concessions granted relative to revenue. The concession accrual included in accrued other expenses on the Company’s consolidated balance sheets was $44,000 and $48,000 as of January 31, 2019 and 2018, respectively. Property and Equipment Property and equipment are stated at cost. Depreciation is computed using the straight-line method, over the estimated useful lives of the related assets. Estimated useful lives are as follows: Computer equipment and software 3‑4 years Office equipment 5 years Office furniture and fixtures 7 years Leasehold improvements Term of lease or estimated useful life, whichever is shorter Depreciation expense for property and equipment in fiscal 2018 and 2017 was $450,000 and $774,000, respectively. Normal repair and maintenance is expensed as incurred. Replacements are capitalized and the property and equipment accounts are relieved of the items being replaced or disposed of, if no longer of value. The related cost and accumulated depreciation of the disposed assets are eliminated and any gain or loss on disposition is included in the results of operations in the year of disposal. Leases On December 13, 2013, the Company entered into an amended lease obligation to lease 24,335 square feet of office space in Atlanta, Georgia. The lease commenced upon taking possession of the space and was scheduled to end in November 2022. The provisions of the lease provided for rent abatement for the first eight months of the lease term. Upon taking possession of the premises, the rent abatement and the unamortized balance of deferred rent associated with the previously leased premises were aggregated with the total expected rental payments and amortized on a straight-line basis over the term of the lease. In the third quarter of fiscal 2018, we assigned our Atlanta office lease and relocated our corporate office to a new space. See Note 12 – Commitments and Contingencies for further details on our new shared office arrangement. In fiscal 2014, the Company entered into a lease obligation to lease 10,350 square feet of office space in New York, New York. The lease commenced upon taking possession of the space and expires in November 2019. The lease agreement provided for rent abatement for the first two months of the lease term. Upon taking possession of the premises, the rent abatement was aggregated with the total expected rental payments and amortized on a straight-line basis over the term of the lease. In the second quarter of fiscal 2018, we closed our New York office and subleased the office space for the remaining period of the original lease term. See Note 4 – Operating Leases for further details on the closure of our New York office. The Company had capital leases to finance office equipment purchases that continued into the third quarter of fiscal 2017. The amortization expense of the leased equipment is included in depreciation expense. As of January 31, 2019 and 2018, the Company had no material capital lease obligations. Debt Issuance Costs Costs related to the issuance of debt are capitalized and amortized to interest expense on a straight-line basis, which is not materially different from the effective interest method, over the term of the related debt. Deferred financing costs are presented on the Company’s consolidated balance sheets as a direct deduction from the carrying amount of the non-current portion of our term loan. Impairment of Long-Lived Assets The Company reviews the carrying value of long-lived assets for impairment whenever facts and circumstances exist that would suggest that assets might be impaired or that the useful lives should be modified. Among the factors the Company considers in making the evaluation are changes in market position and profitability. If facts and circumstances are present which may indicate that the carrying amount of the assets may not be recoverable, the Company will prepare a projection of the undiscounted cash flows of the specific asset or asset group and determine if the long-lived assets are recoverable based on these undiscounted cash flows. If impairment is indicated, an adjustment will be made to reduce the carrying amount of these assets to their fair values. Capitalized Software Development Costs Software development costs associated with the planning and designing phase of software development, including coding and testing activities necessary to establish technological feasibility, are classified as research and development and are expensed as incurred. Once technological feasibility has been determined, a portion of the costs incurred in development, including coding, testing and quality assurance, are capitalized and subsequently reported at the lower of unamortized cost or net realizable value. The Company capitalized such costs, including interest, of $3,003,000 and $1,836,000 in fiscal 2018 and 2017, respectively. Amortization for the Company’s software systems is provided on a solution-by-solution basis over the estimated economic life of the software, typically three to five years, using the straight-line method. Amortization commences when a solution is available for general release to clients. Acquired internally-developed software from acquisitions is amortized using the straight-line method. Amortization expense on all internally-developed software was $1,160,000 and $2,113,000 in fiscal 2018 and 2017, respectively, and was included in the consolidated statements of operations as follows: Fiscal Year 2018 2017 Amortization expense on internally-developed software included in: Cost of systems sales $ 768,000 $ 1,914,000 Cost of software as a service 379,000 186,000 Cost of audit services 13,000 13,000 Total amortization expense on internally-developed software $ 1,160,000 $ 2,113,000 Research and development expense was $4,261,000 and $5,352,000 in fiscal 2018 and 2017, respectively. Fair Value of Financial Instruments The FASB’s authoritative guidance on fair value measurements establishes a framework for measuring fair value, and expands disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. The carrying amount of the Company’s long-term debt approximates fair value since the variable interest rates being paid on the amounts approximate the market interest rate. Long-term debt is classified as Level 2. The table below provides information on our liabilities that are measured at fair value on a recurring basis: Quoted Prices in Significant Other Significant Total Fair Active Markets Observable Inputs Unobservable Inputs Value (Level 1) (Level 2) (Level 3) At January 31, 2019 Royalty liability (1) (3) $ 905,000 $ — $ — $ 905,000 At January 31, 2018 Royalty liability (1) (2) $ 2,469,000 $ — $ — $ 2,469,000 (1) The initial fair value of royalty liability was determined by management with the assistance of an independent third-party valuation specialist, and by management thereafter. Fair value adjustments are included within miscellaneous expense in the consolidated statements of operations. (2) The fair value of the royalty liability was determined based on the probability-weighted revenue scenarios for the Streamline Health® Clinical Analytics solution licensed from Montefiore Medical Center (discussed in Note 12 – Commitments and Contingencies). (3) Following the modification of the Royalty Agreement in the second quarter of fiscal 2018 (discussed in Note 12 – Commitments and Contingencies ), the royalty liability was significantly reduced as a result of the commitment to fulfill a portion of our obligation by providing incremental maintenance services. The fair value of the royalty liability was determined based on the portion of the modified royalty commitment payable in cash. In fiscal 2018, the Company determined that its strategic focus on serving the middle of the revenue cycle and the resulting decrease in the customer base for our Clinical Analytics solution constituted a triggering event for impairment analysis. We assessed the fair value of long-lived assets associated with our Clinical Analytics solution based on expected future cash flows from this solution, including the royalty liability , and determined that related intangible assets and capitalized software development costs classified as Level 3 were fully impaired, therefore had zero value as of December 31, 2018. For further details on the impairment loss and royalty liability associated with our Clinical Analytics solution, see Note 6 – Goodwill and Intangible Assets and Note 12 – Commitments and Contingencies, respectively. Revenue Recognition We derive revenue from the sale of internally-developed software, either by licensing for local installation or by a software as a service (“SaaS”) delivery model, through our direct sales force or through third-party resellers. Licensed, locally-installed clients on a perpetual model utilize our support and maintenance services for a separate fee, whereas term-based locally installed license fees and SaaS fees include support and maintenance. We also derive revenue from professional services that support the implementation, configuration, training and optimization of the applications, as well as audit services provided to help clients review their internal coding audit processes. Additional revenues are also derived from reselling third-party software and hardware components. We recognize revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers (“ASC 606”), the new revenue recognition standard established by ASU 2014‑09. The core principle of ASC 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We commence revenue recognition (Step 5 below) in accordance with that core principle after applying the following steps: · Step 1: Identify the contract(s) with a customer · Step 2: Identify the performance obligations in the contract · Step 3: Determine the transaction price · Step 4: Allocate the transaction price to the performance obligations in the contract · Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation We follow the accounting revenue guidance under ASC 606 to determine whether contracts contain more than one performance obligation. Performance obligations are the unit of accounting for revenue recognition and generally represent the distinct goods or services that are promised to the customer. Revenue is recognized net of any taxes collected from customers and subsequently remitted to governmental authorities. If we determine that we have not satisfied a performance obligation, we will defer recognition of the revenue until the performance obligation is deemed to be satisfied. Maintenance and support and SaaS agreements are generally non-cancelable or contain significant penalties for early cancellation, although clients typically have the right to terminate their contracts for cause if we fail to perform material obligations. However, if non-standard acceptance periods, non-standard performance criteria, or cancellation or right of refund terms are required, revenue is recognized upon the satisfaction of such criteria. Significant judgment is required to determine the standalone selling price (“SSP”) for each performance obligation, the amount allocated to each performance obligation and whether it depicts the amount that the Company expects to receive in exchange for the related product and/or service. As the selling prices of the Company’s software licenses are highly variable, the Company estimates SSP of its software licenses using the residual approach when the software license is sold with other services and observable SSPs exist for the other services. The Company estimates the SSP for maintenance, professional services, and audit services based on observable standalone sales. Contract Combination The Company may execute more than one contract or agreement with a single customer. The Company evaluates whether the agreements were negotiated as a package with a single objective, whether the amount of consideration to be paid in one agreement depends on the price and/or performance of another agreement, or whether the goods or services promised in the agreements represent a single performance obligation. The conclusions reached can impact the allocation of the transaction price to each performance obligation and the timing of revenue recognition related to those arrangements. The Company has utilized the portfolio approach as the practical expedient. We have applied the revenue model to a portfolio of contracts with similar characteristics where we expected that the financial statements would not differ materially from applying it to the individual contracts within that portfolio. Systems Sales The Company’s software license arrangements provide the customer with the right to use functional intellectual property. Implementation, support, and other services are typically considered distinct performance obligations when sold with a software license unless these services are determined to significantly modify the software. Revenue is recognized at a point in time. Typically, this is upon shipment of components or electronic download of software. Maintenance and Support Services Our maintenance and support obligations include multiple discrete performance obligations, with the two largest being unspecified product upgrades or enhancements, and technical support, which can be offered at various points during a contract period. We believe that the multiple discrete performance obligations within our overall maintenance and support obligations can be viewed as a single performance obligation since both the unspecified upgrades and technical support are activities to fulfill the maintenance performance obligation and are rendered concurrently. Maintenance and support agreements entitle clients to technology support, version upgrades, bug fixes and service packs. We recognize maintenance and support revenue over the contract term. Software-Based Solution Professional Services The Company provides various professional services to customers with software licenses. These include project management, software implementation and software modification services. Revenues from arrangements to provide professional services are generally distinct from the other promises in the contract and are recognized as the related services are performed. Consideration payable under these arrangements is either fixed fee or on a time-and-materials basis. Software as a Service SaaS-based contracts include use of the Company’s platform, implementation, support and other services which represent a single promise to provide continuous access to its software solutions. The Company recognizes revenue over time for the life of the contract. We defer the direct costs, which include salaries and benefits, for professional services related to SaaS contracts. These deferred costs will be amortized over the identical term as the associated revenues. As of January 31, 2019 and 2018, we had deferred costs of $251,000 and $471,000, respectively, net of accumulated amortization of $399,000 and $312,000, respectively. Amortization expense of these costs was $346,000 and $270,000 in fiscal 2018 and 2017, respectively. Audit Services The Company provides technology-enabled coding audit services to help clients review and optimize their internal clinical documentation and coding functions across the applicable segment of the client’s enterprise. Audit services are a separate performance obligation. We recognize revenue over time as the services are performed. Comparative GAAP Financials The adoption of the new standard has the following impact to the Company’s condensed consolidated statements of operations for the year ended January 31, 2019: Year Ended January 31, 2019 As reported under Balances without Adjustments due to Revenues Systems sales $ 2,472,000 $ 2,322,000 $ 150,000 Maintenance and support 12,586,000 12,590,000 (4,000) As of January 31, 2019 As reported under Balances without Adjustments due to Assets Contract receivables, current $ 1,263,000 $ 803,000 $ 460,000 Contract receivables, noncurrent 407,000 27,000 380,000 Liabilities Deferred revenues, current 8,338,000 9,084,000 (746,000) Shareholders' Equity Accumulated deficit $ (76,550,000) $ (78,136,000) $ 1,586,000 The adoption of ASC 606 resulted in a decrease in deferred revenues and an increase in contract receivables driven by upfront recognition of revenue, rather than over the contract period, from certain multi-year term software license agreements that include both software licenses and software support and maintenance. Revenues related to SaaS-based offerings, hardware sales, maintenance and support, and audit services remain substantially unchanged. Disaggregation of Revenue The following table provides information about disaggregated revenue by type and nature of revenue stream: Year Ended January 31, 2019 Recurring Revenue Non-recurring Revenue Total Systems sales $ 899,000 $ 1,573,000 $ 2,472,000 Professional services — 1,336,000 1,336,000 Audit services — 1,118,000 1,118,000 Maintenance and support 12,586,000 — 12,586,000 Software as a service 4,853,000 — 4,853,000 Total revenue: $ 18,338,000 $ 4,027,000 $ 22,365,000 Contract Receivables and Deferred Revenues The Company receives payments from customers based upon contractual billing schedules. Contract receivables include amounts related to the Company’s contractual right to consideration for completed performance obligations not yet invoiced. Deferred revenues include payments received in advance of performance under the contract. Our contract receivables and deferred revenue are reported on an individual contract basis at the end of each reporting period. Contract receivables are classified as current or noncurrent based on the timing of when we expect to bill the customer. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to recognize revenue. In the year ended January 31, 2019, we recognized $9,449,000 in revenue from deferred revenues outstanding as of January 31, 2018. The cumulative effect of changes related to the adoption of ASC 606 are reflected in the opening balance of accumulated deficit as shown below: As Reported Adjustments As Adjusted ASSETS Contract receivables, current $ 224,000 $ 283,000 $ 507,000 Contract receivables, noncurrent — 468,000 468,000 LIABILITIES Deferred revenues, current 9,482,000 (689,000) 8,793,000 STOCKHOLDERS' EQUITY Accumulated deficit $ (72,125,000) $ 1,440,000 $ (70,685,000) Transaction price allocated to the remaining performance obligations Revenue allocated to remaining performance obligations represents contracted revenue that will be recognized in future periods, which is comprised of deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. Revenue allocated to remaining performance obligations was $27 million as of January 31, 2019, of which the Company expects to recognize approximately 65% over the next 12 months and the remainder thereafter. Deferred commissions costs (contract acquisition costs) Contract acquisition costs, which consist of sales commissions paid or payable, is considered incremental and recoverable costs of obtaining a contract with a customer. Sales commissions for initial and renewal contracts are deferred and then amortized on a straight-line basis over a period of benefit, which the Company has determined to be the customer life. As a practical expedient, we expense sales commissions as incurred when the amortization period of related deferred commission costs would have been one year or less. Deferred commissions costs paid and payable are included on the consolidated balance sheets within prepaid assets and other current assets, respectively, and totaled $185,000 and $114,000, respectively, as of January 31, 2019. As of January 31, 2018, deferred commissions costs paid and payable totaled $136,000 and $116,000, respectively. In fiscal 2018, $145,000 in amortization expense associated with deferred sales commissions was included in selling, general and administrative expenses on the condensed consolidated statements of operations. Concentrations Financial instruments, which potentially expose the Company to concentrations of credit risk, consist primarily of accounts receivable. The Company’s accounts receivable are concentrated in the healthcare industry. However, the Company’s clients typically are well-established hospitals, medical facilities or major health information systems companies that resell the Company’s solutions that have good credit histories. Payments from clients have been received within normal time frames for the industry. However, some hospitals and medical facilities have experienced significant operating losses as a result of limits on third-party reimbursements from insurance companies and governmental entities and extended payment of receivables from these entities is not uncommon. To date, the Company has relied on a limited number of clients and remarketing partners for a substantial portion of its total revenues. The Company expects that a significant portion of its future revenues will continue to be generated by a limited number of clients and its remarketing partners. The Company currently buys all of its hardware and some major software components of its healthcare information systems from third-party vendors. Although there are a limited number of vendors capable of supplying these components, management believes that other suppliers could provide similar components on comparable terms. Business Combinations The assets acquired, liabilities assumed and contingent consideration are recorded at their fair value on the acquisition date with subsequent changes recognized in earnings. These estimates are inherently uncertain and are subject to refinement. Management develops estimates based on assumptions as a part of the purchase price allocation process to value the assets acquired and liabilities assumed as of the business combination date. As a result, the Company may recognize adjustments to provisional amounts of assets acquired or liabilities assumed in operating expenses in the reporting period in which the adjustments are determined. The Company records acquisition and transaction related expenses in the period in which they are incurred. Acquisition and transaction-related expenses primarily consist of legal, banking, accounting and other advisory fees of third parties associated with potential acquisitions. Goodwill and Intangible Assets Goodwill and other intangible assets were recognized in conjunction with the Interpoint, Meta, CLG and Opportune IT acquisitions, as well as the Unibased acquisition (prior to divestiture of such assets). Identifiable intangible assets include purchased intangible assets with finite lives, which primarily consist of internally-developed software, client relationships, non-compete agreements and license agreements. Finite-lived purchased intangible assets are amortized over their expected period of benefit, which generally ranges from one to 10 years, using the straight-line and undiscounted expected future cash flows methods. The Company assesses the useful lives and possible impairment of intangible assets when an event occurs that may trigger such a review. Factors considered important which could trigger a review include: · significant underperformance relative to historical or projected future operating results; · significant changes in the manner of use of the acquired assets or the strategy for the overall business; · identification of other impaired assets within a reporting unit; · disposition of a significant portion of an operating segment; · significant negative industry or economic trends; · significant decline in the Company’s stock price for a sustained period; and · a decline in the market capitalization relative to the net book value. Determining whether a triggering event has occurred involves significant judgment by the Company. The Company assesses goodwill annually (as of November 1), or more frequently when events and circumstances, such as the ones mentioned above, occur indicating that the recorded goodwill may be impaired. During the years ended January 31, 2019 and 2018, the Company did not note any of the above qualitative factors, which would be considered a triggering event for goodwill impairment. In assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company assesses relevant events and circumstances that may impact the fair value and the carrying amount of a reporting unit. The identification of relevant events and circumstances and how these may impact a reporting unit’s fair value or carrying amount involve significant judgments by management. These judgments include the consideration of macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, events which are specific to the Company and trends in the market price of the Company’s common stock. Each factor is assessed to determine whether it impacts the impairment test positively or negatively, and the magnitude of any such impact. The two-step goodwill impairment test requires the Company to identify its reporting units and to determine estimates of the fair values of those reporting units as of the impairment testing date. Reporting units are determined based on the organizational structure the entity has in place at the date of the impairment test. A reporting unit is an operating segment or component business unit with the following characteristics: (a) it has discrete financial information, (b) segment management regularly reviews its operating results (generally an operating segment has a segment manager who is directly accountable to and maintains regular contact with the chief operating decision maker to discuss operating activities, financial results, forecasts or plans for the segment), and (c) its economic characteristics are dissimilar from other units (this contemplates the nature of the products and services, the nature of the production process, the type or class of customer for the products and services and the methods used to distribute the products and services). The Company determined that it has one operating segment and one reporting unit. To conduct a quantitative two-step goodwill impairment test, the fair value of the reporting unit is first compared to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company performs the second step and records an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. The Company estimates the fair value of its reporting unit using a blend of market and income approaches. The market approach consists of two separate methods, including reference to the Company’s market capitalization, as well as the guideline publicly traded company method. The market capitalization valuation method is based on an analysis of the Company’s stock price on and around the testing date, plus a control premium. The guideline publicly traded company method was made by reference to a list of publicly traded software companies providing services to healthcare organizations, as determined by management. The market value of common equity for each comparable company was derived by multiplying the price per share on the testing date by the total common shares outstanding, plus a control premium. Selected valuation multiples are then determined and applied to appropriate financial statistics based on the Company’s historical and forecasted results. The Company estimates the fair value of its reporting unit using the income approach, via discounted cash flow valuation models which include, but are not limited to, assumptions such as a “risk-free” rate of return on an investment, the weighted average cost of capital of a market participant and future revenue, operating margin, working capital and capital expenditure trends. Determining the fair value of reporting unit and goodwill include

Preferred Stock

Preferred Stock	12 Months Ended
	Jan. 31, 2019
Equity [Abstract]
PREFERRED STOCK	NOTE 3 — PREFERRED STOCK In connection with a 2012 private placement investment, the Company issued 2,416,785 shares of Series A Preferred Stock at $3.00 per share. The Series A Preferred Stock does not pay a dividend, however, the holders are entitled to receive dividends on shares of preferred stock equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock. The Series A Preferred Stock has voting rights on a modified as-if-converted-to-common-stock-basis. The Series A Preferred Stock has a non-participating liquidation right equal to the original issue price plus accrued unpaid dividends, which are senior to the Company’s common stock. The Series A Preferred Stock can be converted to common shares at any time by the holders or, at the option of the Company, if the arithmetic average of the daily volume weighted average price of the common stock for the ten day period prior to the measurement date is greater than $8.00 per share and the average daily trading volume for the sixty day period immediately prior to the measurement date exceeds 100,000 shares. The conversion price is $3.00 per share, subject to certain adjustments. On November 1, 2012, upon shareholder approval, convertible subordinated notes were converted into 1,583,210 shares of Series A Convertible Preferred Stock. Subject to the Subordination and Intercreditor Agreement among the preferred stockholders, the Company and Wells Fargo, each share of Series A Preferred Stock is redeemable at the option of the holder for an amount equal to the initial issuance price of $3.00 (adjusted to reflect stock splits, stock dividends or like events) plus any accrued and unpaid dividends thereon. The Series A Preferred Stock are classified as temporary equity as the securities are redeemable solely at the option of the holder. In fiscal 2018, 54,531 shares of the Company’s Series A Convertible Preferred Stock were converted into common stock. As a result, Series A Convertible Preferred Stock was reduced by $164,000, with the offsetting increase to Common Stock and Additional Paid-in Capital. As of January 31, 2019 and 2018, 2,895,464 and 2,949,995 shares of Series A Convertible Preferred Stock remained outstanding.

Operating Leases

Operating Leases	12 Months Ended
	Jan. 31, 2019
Operating Leases
OPERATING LEASES	NOTE 4 — OPERATING LEASES In the second quarter of fiscal 2018, we closed our New York office and subleased the office space for the remaining period of the original lease term which expires in November 2019. As a result of vacating and subleasing the office, we recorded a $472,000 loss on exit of the operating lease in fiscal 2018 , which captures the future net cash flows associated with the vacated premises as of the office closure date, including $384,000 in rent receipts from our sublessee and $48,000 in loss incurred on the disposal of fixed assets . As of January 31, 2019, the total minimum rentals due and to be received under this non-cancelable sublease were $478,000 and $216,000, respectively. In the third quarter of fiscal 2018, we assigned our then current Atlanta office lease that would have expired in November 2022 and entered into a membership agreement to occupy shared office space in Atlanta. As a result of assigning the office lease, we recorded a $562,000 loss on exit of the operating lease in the third quarter of fiscal 2018, which is mainly comprised of $275,000 in broker commissions and a $499,000 loss on the disposal of leasehold improvements, furniture and equipment , net of a $239,000 gain from the write-off of associated lease incentive liability . See Note 12 – Commitments and Contingencies for further details on our shared office arrangement. Rent and leasing expense for facilities and equipment was $964,000 and $1,234,000 for fiscal years 2018 and 2017, respectively.

Debt

Debt	12 Months Ended
	Jan. 31, 2019
Debt Disclosure [Abstract]
DEBT	NOTE 5 — DEBT Term Loan and Line of Credit On November 21, 2014, we entered into a Credit Agreement (the “Credit Agreement”) with Wells Fargo Bank, N.A., as administrative agent, and other lender parties thereto. Pursuant to the Credit Agreement, the lenders agreed to provide a $10,000,000 senior term loan and a $5,000,000 revolving line of credit to our primary operating subsidiary. Amounts outstanding under the Credit Agreement bear interest at either LIBOR or the base rate, as elected by the Company, plus an applicable margin. Subject to the Company’s leverage ratio, pursuant to the terms of the amendment to the Credit Agreement entered into as of April 15, 2015, the applicable LIBOR rate margin varies from 4.25% to 6.25%, and the applicable base rate margin varies from 3.25% to 5.25%. The term loan and line of credit provide support for working capital, capital expenditures and other general corporate purposes, including permitted acquisitions. The outstanding senior term loan is secured by substantially all of our assets. Pursuant to the terms of the fourth amendment to the Credit Agreement entered into as of November 20, 2018, the original term loan and line of credit maturity date of November 21, 2019 was extended to May 21, 2020. The senior term loan principal balance is payable in quarterly installments, which started in March 2015 and will continue through the maturity date, with the full remaining unpaid principal balance due at maturity. Financing costs associated with the new credit facility are being amortized over its term on a straight-line basis, which is not materially different from the effective interest method. The Credit Agreement includes customary financial covenants, including the requirements that the Company maintain minimum liquidity and achieve certain minimum EBITDA levels (as defined in the Credit Agreement). In addition, the Credit Agreement prohibits the Company from paying dividends on the common and preferred stock. Pursuant to the terms of the Credit Agreement, the Company is required to maintain minimum liquidity of at least (i) $5,000,000 through January 31, 2018, (ii) $4,000,000 from February 1, 2018 through November 19, 2018, (iii) $3,500,000 from November 20, 2018 through and including January 31, 2019, and (iv) $4,000,000 from February 1, 2019 through and including the maturity date of the credit facility. The following table shows our minimum EBITDA covenant thresholds, as modified by the fourth amendment to the Credit Agreement: Applicable period Minimum For the fiscal quarter ended October 31, 2018 $ (509,000) For the 2-quarter period ended January 31, 2019 20,000 For the 3-quarter period ending April 30, 2019 204,000 For the 4-quarter period ending July 31, 2019 180,000 For the 4-quarter period ending October 31, 2019 508,000 For the 4-quarter period ending January 31, 2020 408,000 For the 4-quarter period ending April 30, 2020 and each fiscal quarter thereafter 562,000 The Company was in compliance with the applicable financial loan covenants at January 31, 2019. As of January 31, 2019, the Company had no outstanding borrowings under the revolving line of credit, and had accrued $14,000 in interest and unused line fees. Based upon the borrowing base formula set forth in the Credit Agreement, as of January 31, 2019, the Company had access to the full amount of the $5,000,000 revolving line of credit. Outstanding principal balances on debt consisted of the following at: January 31, 2019 January 31, 2018 Senior term loan $ 4,030,000 $ 4,626,000 Deferred financing cost (82,000) (128,000) Total 3,948,000 4,498,000 Less: Current portion (597,000) (597,000) Non-current portion of debt $ 3,351,000 $ 3,901,000 Future principal payments of debt consisted of the following at January 31, 2019: Fiscal year Senior Term Loan (1) 2019 $ 597,000 2020 3,433,000 Total repayments $ 4,030,000 (1) Term loan balance on the consolidated balance sheet is reported net of deferred financing costs of $82,000.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Jan. 31, 2019
Goodwill and Intangible Assets
GOODWILL AND INTANGIBLE ASSETS	NOTE 6 — GOODWILL AND INTANGIBLE ASSETS Intangible assets consist of the following: January 31, 2019 Estimated Accumulated Useful Life Gross Assets Amortization Net Assets Finite-lived assets: Client relationships 5-10 years $ 5,397,000 $ 3,756,000 $ 1,641,000 Covenants not to compete 3 years 130,000 102,000 28,000 Total $ 5,527,000 $ 3,858,000 $ 1,669,000 January 31, 2018 Estimated Accumulated Useful Life Gross Assets Amortization Net Assets Finite-lived assets: Client relationships 5-15 years 5,805,000 3,308,000 2,497,000 Covenants not to compete 0.5-15 years 986,000 823,000 163,000 Supplier agreements 5 years 1,582,000 1,582,000 — License agreement 15 years 4,431,000 1,256,000 3,175,000 Total $ 12,804,000 $ 6,969,000 $ 5,835,000 In fiscal 2018, we recognized an impairment charge of $3,681,000 as the carrying value of finite-lived intangible assets and capitalized product development cost relating to our Clinical Analytics solution no longer appeared recoverable. This impairment charge is included in the “ Impairment of long-lived assets ” line in our consolidated statements of operations for the year ended January 31, 2019. See Note 12 – Commitments and Contingencies for royalty liability associated with our Clinical Analytics solution. Future amortization expense for intangible assets is estimated as follows: Annual Amortization Expense 2019 $ 554,000 2020 491,000 2021 455,000 2022 169,000 Total $ 1,669,000

Income Taxes

Income Taxes	12 Months Ended
	Jan. 31, 2019
Income Taxes
INCOME TAXES	NOTE 7 — INCOME TAXES Income taxes consist of the following: Fiscal Year 2018 2017 Current tax (expense) benefit: Federal $ 7,000 $ — State (7,000) (11,000) Total current provision — (11,000) Deferred tax benefit: Federal — 95,000 State — — Total deferred tax benefit — 95,000 Current and deferred tax benefit $ — $ 84,000 The income tax benefit differs from the amount computed using the federal statutory income tax rates of 21% and 32.9% for fiscal 2018 and 2017, respectively, as follows: Fiscal Year 2018 2017 Federal tax benefit at statutory rate $ (1,232,000) $ 1,047,000 State and local taxes, net of federal benefit (expense) (95,000) 195,000 Change in valuation allowance (767,000) 4,505,000 Permanent items: Incentive stock options 18,000 (112,000) Change in fair value of warrants liability — 15,000 Other 1,000 (24,000) Reserve for uncertain tax position 32,000 (19,000) R&D Credit (Federal) (158,000) 219,000 R&D Credit (State) 134,000 (129,000) Tax Cuts and Jobs Act — (5,827,000) Expiring carryforwards 1,965,000 — Other 102,000 214,000 Income tax benefit $ — $ 84,000 The Company provides deferred income taxes for temporary differences between assets and liabilities recognized for financial reporting and income tax purposes. The income tax effects of these temporary differences and credits are as follows: January 31, 2019 2018 Deferred tax assets: Allowance for doubtful accounts $ 84,000 $ 91,000 Deferred revenue 63,000 155,000 Accruals 141,000 71,000 Net operating loss carryforwards 9,532,000 10,617,000 Stock compensation expense 205,000 236,000 Property and equipment 30,000 109,000 R&D credit 1,102,000 1,144,000 Other 133,000 117,000 Total deferred tax assets 11,290,000 12,540,000 Valuation allowance (11,045,000) (11,813,000) Net deferred tax assets 245,000 727,000 Deferred tax liabilities: Finite-lived intangible assets (245,000) (727,000) Total deferred tax liabilities (245,000) (727,000) Net deferred tax liabilities $ — $ — At January 31, 2019, the Company had U.S. federal net operating loss carry forwards of $36,800,000, which expire at various dates through fiscal 2037. The Company also had state net operating loss carry forwards of $17,170,000, which expire through fiscal 2038. Federal and state R&D credit carry forwards will expire through fiscal 2038 and 2028, respectively. The Tax Cuts and Jobs Act signed into law on December 22, 2017 eliminated the ability to carryback net operating losses and allows net operating losses to be carried forward indefinitely. At January 31, 2019, the Company had indefinite-lived federal net operating loss carry forwards of $3,900,000. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. The Company established a valuation allowance of $11,045,000 and $11,813,000 at January 31, 2019 and 2018, respectively. The decrease in the valuation allowance of $768,000 was driven primarily by the expiration of federal net operating loss carry forwards. The Company and its subsidiary are subject to U.S. federal income tax as well as income taxes in multiple state and local jurisdictions. The Company has concluded all U.S. federal tax matters for years through January 31, 2014. All material state and local income tax matters have been concluded for years through January 31, 2013. The Company is no longer subject to IRS examination for periods prior to the tax year ended January 31, 2014; however, carryforward losses that were generated prior to the tax year ended January 31, 2014 may still be adjusted by the IRS if they are used in a future period. The Company has recorded a reserve, including interest and penalties, for uncertain tax positions of $275,000 and $295,000 as of January 31, 2019 and 2018, respectively. As of January 31, 2019 and 2018, the Company had no accrued interest and penalties associated with unrecognized tax benefits. A reconciliation of the beginning and ending amounts of gross unrecognized tax benefits (excluding interest and penalties) is as follows: 2018 2017 Beginning of fiscal year $ 295,000 $ 290,000 Additions for tax positions for the current year 32,000 62,000 Additions for tax positions of prior years — 3,000 Subtractions for tax positions of prior years (52,000) (60,000) End of fiscal year $ 275,000 $ 295,000 Impact of the Tax Cuts and Jobs Act The Tax Act was signed into law on December 22, 2017. Among other things, the Tax Act reduces the U.S. federal corporate tax rate from 34.0 percent to 21.0 percent effective January 1, 2018 and allows for 100 percent expensing of certain fixed assets placed in service after September 27, 2017. On December 22, 2017, Staff Accounting Bulletin No. 118 (“SAB 118”) was issued to address the application of U.S. GAAP in situations where a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to finalize the calculations for certain income tax effects of the Tax Cuts and Jobs Act. In accordance with SAB 118, in fiscal 2017 the Company recorded a provisional estimated net tax expense of $5.8 million in connection with the tax effect of the Tax Act. Adjustments to this provisional amount recorded in fiscal 2018 did not have a significant impact on our consolidated financial statements. Our accounting for the effects of the Tax Act enactment is now complete.

Major Clients

Major Clients	12 Months Ended
	Jan. 31, 2019
Major Clients
MAJOR CLIENTS	NOTE 8 — MAJOR CLIENTS In fiscal year 2018, no individual client accounted for 10% or more of our total revenues. Two clients represented 12% and 9%, respectively, of total accounts receivable as of January 31, 2019. In fiscal year 2017, no individual client accounted for 10% or more of our total revenues. Two clients represented 12% and 11%, respectively, of total accounts receivable as of January 31, 2018.

Employee Retirement Plan

Employee Retirement Plan	12 Months Ended
	Jan. 31, 2019
Employee Retirement Plan
EMPLOYEE RETIREMENT PLAN	NOTE 9 — EMPLOYEE RETIREMENT PLAN The Company has established a 401(k) retirement plan that covers all associates. Company contributions to the plan may be made at the discretion of the board of directors. The Company matched 100% up to the first 4% of compensation deferred by each associate in the 401(k) plan through December 31, 2018. Effective January 1, 2019, the Company’s matched amount was decreased to 50% up to the first 4% of compensation deferred by each associate. The total compensation expense for this matching contribution was $483,000 and $524,000 in fiscal 2018 and 2017, respectively.

Employee Stock Purchase Plan

Employee Stock Purchase Plan	12 Months Ended
	Jan. 31, 2019
Stock-Based Compensation
EMPLOYEE STOCK PURCHASE PLAN	NOTE 10 — EMPLOYEE STOCK PURCHASE PLAN The Company has an Employee Stock Purchase Plan under which associates may purchase up to 1,000,000 shares of common stock. Under the plan, eligible associates may elect to contribute, through payroll deductions, up to 10% of their base pay to a trust during any plan year, i.e., January 1 through December 31 of the same year. Semi-annually, typically in January and July of each year, the plan issues, for the benefit of the employees, shares of common stock at the lesser of (a) 85% of the fair market value of the common stock on the first day of the vesting period (January 1 or July 1), or (b) 85% of the fair market value of the common stock on the last day of the vesting period (June 30 or December 31 of the same year). At January 31, 2019, 431,556 shares remain that can be purchased under the plan. The Company recognized compensation expense of $4,000 and $19,000 for fiscal years 2018 and 2017, respectively, under this plan. During fiscal 2018, 13,339 shares were purchased at the price of $0.69 per share and 10,370 shares were purchased at the price of $1.20 per share; during fiscal 2017, 21,234 shares were purchased at the price of $0.98 per share and 26,048 shares were purchased at the price of $0.91 per share. The cash received for shares purchased from the plan was $22,000 and $45,000 in fiscal 2018 and 2017, respectively. The purchase price at June 30, 2019 will be 85% of the lower of (a) the closing price on January 2, 2019 ($0.88) or (b) the closing price on June 30, 2019.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Jan. 31, 2019
Stock-Based Compensation
STOCK-BASED COMPENSATION	NOTE 11 — STOCK-BASED COMPENSATION Stock Option Plans The Company’s Second Amended and Restated 2013 Stock Incentive Plan (the “2013 Plan”) replaced the 2005 Incentive Compensation Plan (the “2005 Plan”). Under these plans, the Company is authorized to issue equity awards (stock options, stock appreciation rights or “SARs”, and restricted stock) to directors and associates of the Company. Outstanding awards under the 2005 Plan continue to be governed by the terms of the 2005 Plan until exercised, expired or otherwise terminated or canceled, but no further equity awards are allowed to be granted under the 2005 Plan. Under the 2013 Plan, the Company is authorized to issue a number of shares not to exceed (i) 2,300,000 plus (ii) the number of shares remaining available for issuance under the 2005 Plan as of the date the 2005 Plan was replaced, plus (iii) the number of shares that become available under the 2005 Plan pursuant to forfeiture, termination, lapse, or satisfaction of a 2005 Plan award in cash or property other than shares of common stock. The options granted under the 2013 Plan and 2005 Plan have terms of ten years or less, and typically vest and become fully exercisable ratably over three years of continuous service to the Company from the date of grant. At January 31, 2019 and 2018, options to purchase 1,355,657 and 1,873,156 shares of the Company’s common stock, respectively, have been granted and are outstanding under the 2013 Plan. There are no SARs outstanding. Inducement grants are approved by the Company’s compensation committee pursuant to NASDAQ Marketplace Rule 5635(c)(4). The terms of the grants were nearly identical to the terms and conditions of the Company’s stock incentive plans in effect at the time of each inducement grant. For the year ended January 31, 2019, with regard to inducement grants, no stock options were issued, no options expired, 75,000 options were forfeited and no stock options were exercised. For the year ended January 31, 2018, with regard to inducement grants, no stock options were issued, no options expired, no options were forfeited and no stock options were exercised. As of January 31, 2019 and 2018, there were 225,000 and 300,000 options outstanding, respectively, under inducement grants. Please see “Restricted Stock” section for information on the restricted shares. A summary of stock option activity follows: Weighted Average Remaining Aggregate Options Exercise Price Life in Years intrinsic value Outstanding as of February 1, 2018 2,173,156 $ 3.42 Granted 47,000 1.68 Exercised (50,694) 1.18 Expired (201,469) 2.55 Forfeited (387,336) 3.61 Outstanding as of January 31, 2019 1,580,657 $ 3.50 6.13 $ 15,000 Exercisable as of January 31, 2019 1,401,435 $ 3.73 5.91 $ 8,000 Vested or expected to vest as of January 31, 2019 1,542,516 $ 3.54 6.09 $ 14,000 (1) The exercise prices range from $1.10 to $8.10, of which 440,000 shares are between $1.10 and $2.00 per share, 362,240 shares are between $2.19 and $4.00 per share, and 778,417 shares are between $4.02 and $8.10 per share. (2) The exercise prices range from $1.18 to $8.10, of which 280,778 shares are between $1.18 and $2.00 per share, 362,240 shares are between $2.19 and $4.00 per share, and 758,417 shares are between $4.02 and $8.10 per share. For fiscal 2018 and 2017, the weighted average grant date fair value of options granted during the year was $1.03 and $0.65, respectively, and the total intrinsic value of options exercised during the year was $13,000 and zero for fiscal 2018 and 2017, respectively. The fiscal 2018 and 2017 stock-based compensation was estimated at the date of grant using a Black-Scholes option pricing model with the following weighted average assumptions for each fiscal year: 2018 2017 Expected life 6 years 6 years Risk-free interest rate 2.89 % 2.65 % Weighted average volatility factor 0.65 0.65 Dividend yield — — Forfeiture rate 20 % 13 % At January 31, 2019, there was $98,000 of unrecognized compensation cost related to non-vested stock-option awards. That cost is expected to be recognized over a remaining weighted average period of 0.6 years. The expense associated with stock option awards was $244,000 and $563,000, respectively, for fiscal 2018 and 2017. Cash received from the exercise of options was zero in both fiscal 2018 and 2017. The 2005 Plan and the 2013 Plan contain change in control provisions whereby any outstanding equity awards under the plans subject to vesting, which have not fully vested as of the date of the change in control, shall automatically vest and become immediately exercisable. One of the change in control provisions is deemed to occur if there is a change in beneficial ownership, or authority to vote, directly or indirectly, of securities representing 20% or more of the total of all of the Company’s then-outstanding voting securities, unless through a transaction arranged by or consummated with the prior approval of the Board of Directors. Other change in control provisions relate to mergers and acquisitions or a determination of change in control by the Company’s Board of Directors. Restricted Stock The Company is authorized to grant restricted stock awards to associates and directors under the 2013 Plan. The Company has also issued restricted stock as inducement grants to certain new employees. The restrictions on the shares granted generally lapse over a one- to four-year term of continuous employment from the date of grant. The grant date fair value per share of restricted stock, which is based on the closing price of our common stock on the grant date, is expensed on a straight-line basis as the restriction period lapses. The shares represented by restricted stock awards are considered outstanding at the grant date, as the recipients are entitled to voting rights. A summary of restricted stock award activity for fiscal 2018 and 2017 is presented below: Weighted Non-vested Average Number of Grant Date Shares Fair Value Non-vested balance at January 31, 2017 858,225 $ 1.59 Granted 295,337 1.17 Vested (331,975) 1.47 Forfeited — — Non-vested balance at January 31, 2018 821,587 $ 1.59 Granted 826,666 1.15 Vested (453,537) 1.34 Forfeited (130,850) 1.61 Non-vested balance at January 31, 2019 1,063,866 $ 1.27 At January 31, 2019, there was $1,110,000 of unrecognized compensation cost related to restricted stock awards. That cost is expected to be recognized over a remaining period of 2.3 years. The expense associated with restricted stock awards was $383,000 and $546,000, respectively, for fiscal 2018 and 2017.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jan. 31, 2019
Commitments and Contingencies
COMMITMENTS AND CONTINGENCIES	NOTE 12 — COMMITMENTS AND CONTINGENCIES Membership agreement to occupy shared office space In fiscal 2018, the Company entered into a membership agreement to occupy shared office space in Atlanta, Georgia. Our new shared office arrangement commenced upon taking possession of the space and ends in November 2020. Fees due under the membership agreement are based on the number of contracted seats and the use of optional office services. As of January 31, 2019, minimum fees due under the shared office arrangement totaled $286,000. Royalty Liability On October 25, 2013, we entered into a Software License and Royalty Agreement (the “Royalty Agreement”) with Montefiore Medical Center (“Montefiore”) pursuant to which Montefiore granted us an exclusive, worldwide 15‑year license of Montefiore’s proprietary clinical analytics platform solution, Clinical Looking Glass® (“CLG”), now known as our Clinical Analytics solution. In addition, Montefiore assigned to us the existing license agreement with a customer using CLG. As consideration under the Royalty Agreement, we paid Montefiore a one-time initial base royalty fee of $3,000,000. Additionally, we originally committed that Montefiore would receive at least an additional $3,000,000 of on-going royalty payments related to future sublicensing of CLG by us within the first six and one-half years of the license term. On July 1, 2018, we entered into a joint amendment to the Royalty Agreement and the existing Software License and Support Agreement with Montefiore to modify the payment obligations of the parties under both agreements. According to the modified provisions, our obligation to pay on-going royalties under the Royalty Agreement was replaced with the obligation to (i) provide maintenance services for 24 months and waive associated maintenance fees, and (ii) pay $1,000,000 in cash by July 31, 2020. As a result of the commitment to fulfill a portion of our obligation by providing maintenance services at no cost, the royalty liability was significantly reduced, with a corresponding increase to deferred revenues. As of January 31, 2019, we had $1,172,000 in deferred revenues associated with this modified royalty liability. The fair value of the royalty liability as of January 31, 2019 was determined based on the amount payable in cash. As of January 31, 2019 and 2018, the present value of this royalty liability was $905,000 and $2,469,000, respectively. Litigation We are, from time to time, a party to various legal proceedings and claims, which arise in the ordinary course of business. We are not aware of any legal matters that could have a material adverse effect on the Company’s consolidated results of operations, financial position or cash flows.

Subsequent Events

Subsequent Events	12 Months Ended
	Jan. 31, 2019
Subsequent Events
SUBSEQUENT EVENTS	NOTE 13 — SUBSEQUENT EVENTS We have evaluated subsequent events occurring after January 31, 2019, and based on our evaluation we did not identify any events that would have required recognition or disclosure in these consolidated financial statements.

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts and Reserves	12 Months Ended
	Jan. 31, 2019
Valuation and Qualifying Accounts
Schedule II - Valuation and Qualifying Accounts and Reserves	Schedule II Valuation and Qualifying Accounts and Reserves Streamline Health Solutions, Inc. For the two years ended January 31, 2019 Additions Balance at Charged to Charged to Beginning of Costs and Other Balance at Description Period Expenses Accounts Deductions End of Period (in thousands) Year ended January 31, 2019: Allowance for doubtful accounts $ 349 $ 13 $ — $ (17) $ 345 Year ended January 31, 2018: Allowance for doubtful accounts $ 198 $ 234 $ — $ (83) $ 349

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Jan. 31, 2019
Significant Accounting Policies
Basis of Presentation	Basis of Presentation The consolidated financial statements include the accounts of Streamline Health Solutions, Inc. and its wholly-owned subsidiary, Streamline Health, Inc. All significant intercompany transactions and balances are eliminated in consolidation. All amounts in the consolidated financial statements, notes and tables have been rounded to the nearest thousand dollars, except share and per share amounts, unless otherwise indicated.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates and judgments, including those related to stock-based compensation, capitalization of software development costs, intangible assets, allowance for doubtful accounts, and income taxes. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash demand deposits. Cash deposits are placed in Federal Deposit Insurance Corporation (“FDIC”) insured financial institutions. Cash deposits may exceed FDIC insured levels from time to time. For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly-liquid investments purchased with an original maturity of three months or less to be cash equivalents.
Receivables and Allowance for Doubtful Accounts	Receivables Accounts and contract receivables are comprised of amounts owed to the Company for licensed software, professional services, including coding audit, maintenance services, and software as a service and are presented net of the allowance for doubtful accounts. The timing of revenue recognition may not coincide with the billing terms of the client contract, resulting in unbilled receivables or deferred revenues; therefore certain contract receivables represent revenues recognized prior to client billings. Individual contract terms with clients or resellers determine when receivables are due. For billings where the criteria for revenue recognition have not been met, deferred revenue is recorded until all revenue recognition criteria have been met. Allowance for Doubtful Accounts In determining the allowance for doubtful accounts, aged receivables are analyzed periodically by management. Each identified receivable is reviewed based upon the most recent information available and the status of any open or unresolved issues with the client preventing the payment thereof. Corrective action, if necessary, is taken by the Company to resolve open issues related to unpaid receivables. During these periodic reviews, the Company determines the required allowances for doubtful accounts for estimated losses resulting from the unwillingness or inability of its clients or resellers to make required payments. The allowance for doubtful accounts was approximately $345,000 and $349,000 at January 31, 2019 and 2018, respectively. The Company believes that its reserve is adequate, however results may differ in future periods. Bad debt expense for fiscal years 2018 and 2017 was as follows: 2018 2017 Bad debt expense $ 13,000 $ 234,000
Concessions Accrual	Concessions Accrual In determining the concessions accrual, the Company evaluates historical concessions granted relative to revenue. The concession accrual included in accrued other expenses on the Company’s consolidated balance sheets was $44,000 and $48,000 as of January 31, 2019 and 2018, respectively.
Property and Equipment	Property and Equipment Property and equipment are stated at cost. Depreciation is computed using the straight-line method, over the estimated useful lives of the related assets. Estimated useful lives are as follows: Computer equipment and software 3‑4 years Office equipment 5 years Office furniture and fixtures 7 years Leasehold improvements Term of lease or estimated useful life, whichever is shorter Depreciation expense for property and equipment in fiscal 2018 and 2017 was $450,000 and $774,000, respectively. Normal repair and maintenance is expensed as incurred. Replacements are capitalized and the property and equipment accounts are relieved of the items being replaced or disposed of, if no longer of value. The related cost and accumulated depreciation of the disposed assets are eliminated and any gain or loss on disposition is included in the results of operations in the year of disposal.
Leases	Leases On December 13, 2013, the Company entered into an amended lease obligation to lease 24,335 square feet of office space in Atlanta, Georgia. The lease commenced upon taking possession of the space and was scheduled to end in November 2022. The provisions of the lease provided for rent abatement for the first eight months of the lease term. Upon taking possession of the premises, the rent abatement and the unamortized balance of deferred rent associated with the previously leased premises were aggregated with the total expected rental payments and amortized on a straight-line basis over the term of the lease. In the third quarter of fiscal 2018, we assigned our Atlanta office lease and relocated our corporate office to a new space. See Note 12 – Commitments and Contingencies for further details on our new shared office arrangement. In fiscal 2014, the Company entered into a lease obligation to lease 10,350 square feet of office space in New York, New York. The lease commenced upon taking possession of the space and expires in November 2019. The lease agreement provided for rent abatement for the first two months of the lease term. Upon taking possession of the premises, the rent abatement was aggregated with the total expected rental payments and amortized on a straight-line basis over the term of the lease. In the second quarter of fiscal 2018, we closed our New York office and subleased the office space for the remaining period of the original lease term. See Note 4 – Operating Leases for further details on the closure of our New York office. The Company had capital leases to finance office equipment purchases that continued into the third quarter of fiscal 2017. The amortization expense of the leased equipment is included in depreciation expense. As of January 31, 2019 and 2018, the Company had no material capital lease obligations.
Debt Issuance Costs	Debt Issuance Costs Costs related to the issuance of debt are capitalized and amortized to interest expense on a straight-line basis, which is not materially different from the effective interest method, over the term of the related debt. Deferred financing costs are presented on the Company’s consolidated balance sheets as a direct deduction from the carrying amount of the non-current portion of our term loan.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews the carrying value of long-lived assets for impairment whenever facts and circumstances exist that would suggest that assets might be impaired or that the useful lives should be modified. Among the factors the Company considers in making the evaluation are changes in market position and profitability. If facts and circumstances are present which may indicate that the carrying amount of the assets may not be recoverable, the Company will prepare a projection of the undiscounted cash flows of the specific asset or asset group and determine if the long-lived assets are recoverable based on these undiscounted cash flows. If impairment is indicated, an adjustment will be made to reduce the carrying amount of these assets to their fair values.
Capitalized Software Development Costs	Capitalized Software Development Costs Software development costs associated with the planning and designing phase of software development, including coding and testing activities necessary to establish technological feasibility, are classified as research and development and are expensed as incurred. Once technological feasibility has been determined, a portion of the costs incurred in development, including coding, testing and quality assurance, are capitalized and subsequently reported at the lower of unamortized cost or net realizable value. The Company capitalized such costs, including interest, of $3,003,000 and $1,836,000 in fiscal 2018 and 2017, respectively. Amortization for the Company’s software systems is provided on a solution-by-solution basis over the estimated economic life of the software, typically three to five years, using the straight-line method. Amortization commences when a solution is available for general release to clients. Acquired internally-developed software from acquisitions is amortized using the straight-line method. Amortization expense on all internally-developed software was $1,160,000 and $2,113,000 in fiscal 2018 and 2017, respectively, and was included in the consolidated statements of operations as follows: Fiscal Year 2018 2017 Amortization expense on internally-developed software included in: Cost of systems sales $ 768,000 $ 1,914,000 Cost of software as a service 379,000 186,000 Cost of audit services 13,000 13,000 Total amortization expense on internally-developed software $ 1,160,000 $ 2,113,000 Research and development expense was $4,261,000 and $5,352,000 in fiscal 2018 and 2017, respectively.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The FASB’s authoritative guidance on fair value measurements establishes a framework for measuring fair value, and expands disclosure about fair value measurements. This guidance enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. Under this guidance, assets and liabilities carried at fair value must be classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Cash and cash equivalents are classified as Level 1. The carrying amount of the Company’s long-term debt approximates fair value since the variable interest rates being paid on the amounts approximate the market interest rate. Long-term debt is classified as Level 2. The table below provides information on our liabilities that are measured at fair value on a recurring basis: Quoted Prices in Significant Other Significant Total Fair Active Markets Observable Inputs Unobservable Inputs Value (Level 1) (Level 2) (Level 3) At January 31, 2019 Royalty liability (1) (3) $ 905,000 $ — $ — $ 905,000 At January 31, 2018 Royalty liability (1) (2) $ 2,469,000 $ — $ — $ 2,469,000 (1) The initial fair value of royalty liability was determined by management with the assistance of an independent third-party valuation specialist, and by management thereafter. Fair value adjustments are included within miscellaneous expense in the consolidated statements of operations. (2) The fair value of the royalty liability was determined based on the probability-weighted revenue scenarios for the Streamline Health® Clinical Analytics solution licensed from Montefiore Medical Center (discussed in Note 12 – Commitments and Contingencies). (3) Following the modification of the Royalty Agreement in the second quarter of fiscal 2018 (discussed in Note 12 – Commitments and Contingencies ), the royalty liability was significantly reduced as a result of the commitment to fulfill a portion of our obligation by providing incremental maintenance services. The fair value of the royalty liability was determined based on the portion of the modified royalty commitment payable in cash. In fiscal 2018, the Company determined that its strategic focus on serving the middle of the revenue cycle and the resulting decrease in the customer base for our Clinical Analytics solution constituted a triggering event for impairment analysis. We assessed the fair value of long-lived assets associated with our Clinical Analytics solution based on expected future cash flows from this solution, including the royalty liability , and determined that related intangible assets and capitalized software development costs classified as Level 3 were fully impaired, therefore had zero value as of December 31, 2018. For further details on the impairment loss and royalty liability associated with our Clinical Analytics solution, see Note 6 – Goodwill and Intangible Assets and Note 12 – Commitments and Contingencies, respectively.
Revenue Recognition	Revenue Recognition We derive revenue from the sale of internally-developed software, either by licensing for local installation or by a software as a service (“SaaS”) delivery model, through our direct sales force or through third-party resellers. Licensed, locally-installed clients on a perpetual model utilize our support and maintenance services for a separate fee, whereas term-based locally installed license fees and SaaS fees include support and maintenance. We also derive revenue from professional services that support the implementation, configuration, training and optimization of the applications, as well as audit services provided to help clients review their internal coding audit processes. Additional revenues are also derived from reselling third-party software and hardware components. We recognize revenue in accordance with Accounting Standards Codification (ASC) 606, Revenue from Contracts with Customers (“ASC 606”), the new revenue recognition standard established by ASU 2014‑09. The core principle of ASC 606 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. We commence revenue recognition (Step 5 below) in accordance with that core principle after applying the following steps: · Step 1: Identify the contract(s) with a customer · Step 2: Identify the performance obligations in the contract · Step 3: Determine the transaction price · Step 4: Allocate the transaction price to the performance obligations in the contract · Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation We follow the accounting revenue guidance under ASC 606 to determine whether contracts contain more than one performance obligation. Performance obligations are the unit of accounting for revenue recognition and generally represent the distinct goods or services that are promised to the customer. Revenue is recognized net of any taxes collected from customers and subsequently remitted to governmental authorities. If we determine that we have not satisfied a performance obligation, we will defer recognition of the revenue until the performance obligation is deemed to be satisfied. Maintenance and support and SaaS agreements are generally non-cancelable or contain significant penalties for early cancellation, although clients typically have the right to terminate their contracts for cause if we fail to perform material obligations. However, if non-standard acceptance periods, non-standard performance criteria, or cancellation or right of refund terms are required, revenue is recognized upon the satisfaction of such criteria. Significant judgment is required to determine the standalone selling price (“SSP”) for each performance obligation, the amount allocated to each performance obligation and whether it depicts the amount that the Company expects to receive in exchange for the related product and/or service. As the selling prices of the Company’s software licenses are highly variable, the Company estimates SSP of its software licenses using the residual approach when the software license is sold with other services and observable SSPs exist for the other services. The Company estimates the SSP for maintenance, professional services, and audit services based on observable standalone sales. Contract Combination The Company may execute more than one contract or agreement with a single customer. The Company evaluates whether the agreements were negotiated as a package with a single objective, whether the amount of consideration to be paid in one agreement depends on the price and/or performance of another agreement, or whether the goods or services promised in the agreements represent a single performance obligation. The conclusions reached can impact the allocation of the transaction price to each performance obligation and the timing of revenue recognition related to those arrangements. The Company has utilized the portfolio approach as the practical expedient. We have applied the revenue model to a portfolio of contracts with similar characteristics where we expected that the financial statements would not differ materially from applying it to the individual contracts within that portfolio. Systems Sales The Company’s software license arrangements provide the customer with the right to use functional intellectual property. Implementation, support, and other services are typically considered distinct performance obligations when sold with a software license unless these services are determined to significantly modify the software. Revenue is recognized at a point in time. Typically, this is upon shipment of components or electronic download of software. Maintenance and Support Services Our maintenance and support obligations include multiple discrete performance obligations, with the two largest being unspecified product upgrades or enhancements, and technical support, which can be offered at various points during a contract period. We believe that the multiple discrete performance obligations within our overall maintenance and support obligations can be viewed as a single performance obligation since both the unspecified upgrades and technical support are activities to fulfill the maintenance performance obligation and are rendered concurrently. Maintenance and support agreements entitle clients to technology support, version upgrades, bug fixes and service packs. We recognize maintenance and support revenue over the contract term. Software-Based Solution Professional Services The Company provides various professional services to customers with software licenses. These include project management, software implementation and software modification services. Revenues from arrangements to provide professional services are generally distinct from the other promises in the contract and are recognized as the related services are performed. Consideration payable under these arrangements is either fixed fee or on a time-and-materials basis. Software as a Service SaaS-based contracts include use of the Company’s platform, implementation, support and other services which represent a single promise to provide continuous access to its software solutions. The Company recognizes revenue over time for the life of the contract. We defer the direct costs, which include salaries and benefits, for professional services related to SaaS contracts. These deferred costs will be amortized over the identical term as the associated revenues. As of January 31, 2019 and 2018, we had deferred costs of $251,000 and $471,000, respectively, net of accumulated amortization of $399,000 and $312,000, respectively. Amortization expense of these costs was $346,000 and $270,000 in fiscal 2018 and 2017, respectively. Audit Services The Company provides technology-enabled coding audit services to help clients review and optimize their internal clinical documentation and coding functions across the applicable segment of the client’s enterprise. Audit services are a separate performance obligation. We recognize revenue over time as the services are performed. Comparative GAAP Financials The adoption of the new standard has the following impact to the Company’s condensed consolidated statements of operations for the year ended January 31, 2019: Year Ended January 31, 2019 As reported under Balances without Adjustments due to Revenues Systems sales $ 2,472,000 $ 2,322,000 $ 150,000 Maintenance and support 12,586,000 12,590,000 (4,000) As of January 31, 2019 As reported under Balances without Adjustments due to Assets Contract receivables, current $ 1,263,000 $ 803,000 $ 460,000 Contract receivables, noncurrent 407,000 27,000 380,000 Liabilities Deferred revenues, current 8,338,000 9,084,000 (746,000) Shareholders' Equity Accumulated deficit $ (76,550,000) $ (78,136,000) $ 1,586,000 The adoption of ASC 606 resulted in a decrease in deferred revenues and an increase in contract receivables driven by upfront recognition of revenue, rather than over the contract period, from certain multi-year term software license agreements that include both software licenses and software support and maintenance. Revenues related to SaaS-based offerings, hardware sales, maintenance and support, and audit services remain substantially unchanged. Disaggregation of Revenue The following table provides information about disaggregated revenue by type and nature of revenue stream: Year Ended January 31, 2019 Recurring Revenue Non-recurring Revenue Total Systems sales $ 899,000 $ 1,573,000 $ 2,472,000 Professional services — 1,336,000 1,336,000 Audit services — 1,118,000 1,118,000 Maintenance and support 12,586,000 — 12,586,000 Software as a service 4,853,000 — 4,853,000 Total revenue: $ 18,338,000 $ 4,027,000 $ 22,365,000 Contract Receivables and Deferred Revenues The Company receives payments from customers based upon contractual billing schedules. Contract receivables include amounts related to the Company’s contractual right to consideration for completed performance obligations not yet invoiced. Deferred revenues include payments received in advance of performance under the contract. Our contract receivables and deferred revenue are reported on an individual contract basis at the end of each reporting period. Contract receivables are classified as current or noncurrent based on the timing of when we expect to bill the customer. Deferred revenue is classified as current or noncurrent based on the timing of when we expect to recognize revenue. In the year ended January 31, 2019, we recognized $9,449,000 in revenue from deferred revenues outstanding as of January 31, 2018. The cumulative effect of changes related to the adoption of ASC 606 are reflected in the opening balance of accumulated deficit as shown below: As Reported Adjustments As Adjusted ASSETS Contract receivables, current $ 224,000 $ 283,000 $ 507,000 Contract receivables, noncurrent — 468,000 468,000 LIABILITIES Deferred revenues, current 9,482,000 (689,000) 8,793,000 STOCKHOLDERS' EQUITY Accumulated deficit $ (72,125,000) $ 1,440,000 $ (70,685,000) Transaction price allocated to the remaining performance obligations Revenue allocated to remaining performance obligations represents contracted revenue that will be recognized in future periods, which is comprised of deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. Revenue allocated to remaining performance obligations was $27 million as of January 31, 2019, of which the Company expects to recognize approximately 65% over the next 12 months and the remainder thereafter. Deferred commissions costs (contract acquisition costs) Contract acquisition costs, which consist of sales commissions paid or payable, is considered incremental and recoverable costs of obtaining a contract with a customer. Sales commissions for initial and renewal contracts are deferred and then amortized on a straight-line basis over a period of benefit, which the Company has determined to be the customer life. As a practical expedient, we expense sales commissions as incurred when the amortization period of related deferred commission costs would have been one year or less. Deferred commissions costs paid and payable are included on the consolidated balance sheets within prepaid assets and other current assets, respectively, and totaled $185,000 and $114,000, respectively, as of January 31, 2019. As of January 31, 2018, deferred commissions costs paid and payable totaled $136,000 and $116,000, respectively. In fiscal 2018, $145,000 in amortization expense associated with deferred sales commissions was included in selling, general and administrative expenses on the condensed consolidated statements of operations.
Concentrations	Concentrations Financial instruments, which potentially expose the Company to concentrations of credit risk, consist primarily of accounts receivable. The Company’s accounts receivable are concentrated in the healthcare industry. However, the Company’s clients typically are well-established hospitals, medical facilities or major health information systems companies that resell the Company’s solutions that have good credit histories. Payments from clients have been received within normal time frames for the industry. However, some hospitals and medical facilities have experienced significant operating losses as a result of limits on third-party reimbursements from insurance companies and governmental entities and extended payment of receivables from these entities is not uncommon. To date, the Company has relied on a limited number of clients and remarketing partners for a substantial portion of its total revenues. The Company expects that a significant portion of its future revenues will continue to be generated by a limited number of clients and its remarketing partners. The Company currently buys all of its hardware and some major software components of its healthcare information systems from third-party vendors. Although there are a limited number of vendors capable of supplying these components, management believes that other suppliers could provide similar components on comparable terms.
Business Combinations	Business Combinations The assets acquired, liabilities assumed and contingent consideration are recorded at their fair value on the acquisition date with subsequent changes recognized in earnings. These estimates are inherently uncertain and are subject to refinement. Management develops estimates based on assumptions as a part of the purchase price allocation process to value the assets acquired and liabilities assumed as of the business combination date. As a result, the Company may recognize adjustments to provisional amounts of assets acquired or liabilities assumed in operating expenses in the reporting period in which the adjustments are determined. The Company records acquisition and transaction related expenses in the period in which they are incurred. Acquisition and transaction-related expenses primarily consist of legal, banking, accounting and other advisory fees of third parties associated with potential acquisitions.
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill and other intangible assets were recognized in conjunction with the Interpoint, Meta, CLG and Opportune IT acquisitions, as well as the Unibased acquisition (prior to divestiture of such assets). Identifiable intangible assets include purchased intangible assets with finite lives, which primarily consist of internally-developed software, client relationships, non-compete agreements and license agreements. Finite-lived purchased intangible assets are amortized over their expected period of benefit, which generally ranges from one to 10 years, using the straight-line and undiscounted expected future cash flows methods. The Company assesses the useful lives and possible impairment of intangible assets when an event occurs that may trigger such a review. Factors considered important which could trigger a review include: · significant underperformance relative to historical or projected future operating results; · significant changes in the manner of use of the acquired assets or the strategy for the overall business; · identification of other impaired assets within a reporting unit; · disposition of a significant portion of an operating segment; · significant negative industry or economic trends; · significant decline in the Company’s stock price for a sustained period; and · a decline in the market capitalization relative to the net book value. Determining whether a triggering event has occurred involves significant judgment by the Company. The Company assesses goodwill annually (as of November 1), or more frequently when events and circumstances, such as the ones mentioned above, occur indicating that the recorded goodwill may be impaired. During the years ended January 31, 2019 and 2018, the Company did not note any of the above qualitative factors, which would be considered a triggering event for goodwill impairment. In assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company assesses relevant events and circumstances that may impact the fair value and the carrying amount of a reporting unit. The identification of relevant events and circumstances and how these may impact a reporting unit’s fair value or carrying amount involve significant judgments by management. These judgments include the consideration of macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, events which are specific to the Company and trends in the market price of the Company’s common stock. Each factor is assessed to determine whether it impacts the impairment test positively or negatively, and the magnitude of any such impact. The two-step goodwill impairment test requires the Company to identify its reporting units and to determine estimates of the fair values of those reporting units as of the impairment testing date. Reporting units are determined based on the organizational structure the entity has in place at the date of the impairment test. A reporting unit is an operating segment or component business unit with the following characteristics: (a) it has discrete financial information, (b) segment management regularly reviews its operating results (generally an operating segment has a segment manager who is directly accountable to and maintains regular contact with the chief operating decision maker to discuss operating activities, financial results, forecasts or plans for the segment), and (c) its economic characteristics are dissimilar from other units (this contemplates the nature of the products and services, the nature of the production process, the type or class of customer for the products and services and the methods used to distribute the products and services). The Company determined that it has one operating segment and one reporting unit. To conduct a quantitative two-step goodwill impairment test, the fair value of the reporting unit is first compared to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company performs the second step and records an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value. The Company estimates the fair value of its reporting unit using a blend of market and income approaches. The market approach consists of two separate methods, including reference to the Company’s market capitalization, as well as the guideline publicly traded company method. The market capitalization valuation method is based on an analysis of the Company’s stock price on and around the testing date, plus a control premium. The guideline publicly traded company method was made by reference to a list of publicly traded software companies providing services to healthcare organizations, as determined by management. The market value of common equity for each comparable company was derived by multiplying the price per share on the testing date by the total common shares outstanding, plus a control premium. Selected valuation multiples are then determined and applied to appropriate financial statistics based on the Company’s historical and forecasted results. The Company estimates the fair value of its reporting unit using the income approach, via discounted cash flow valuation models which include, but are not limited to, assumptions such as a “risk-free” rate of return on an investment, the weighted average cost of capital of a market participant and future revenue, operating margin, working capital and capital expenditure trends. Determining the fair value of reporting unit and goodwill includes significant judgment by management, and different judgments could yield different results. The Company performed its annual assessment of goodwill during the fourth quarter of fiscal 2018, using the two-step approach described above. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of a reporting unit with its carrying amount, including goodwill. Based on the analysis performed for step one, the fair value of the reporting unit exceeded the carrying amount of the reporting unit, including goodwill, and, therefore, a goodwill impairment loss was not recognized. As the Company passed step one of the analysis, step two was not required. In fiscal 2018, long-lived assets associated with our Clinical Analytics solution were deemed impaired and their corresponding balance was fully written off (see Note 6 - Goodwill and Intangible Assets to our consolidated financial statements included herein).
Equity Awards	Equity Awards The Company accounts for share-based payments based on the grant-date fair value of the awards with compensation cost recognized as expense over the requisite service period. The Company incurred total annual compensation expense related to stock-based awards of $629,000 and $1,109,000 in fiscal 2018 and 2017, respectively. The fair value of the stock options granted in fiscal 2018 and 2017 was estimated at the date of grant using a Black-Scholes option pricing model. Option pricing model input assumptions such as expected term, expected volatility and risk-free interest rate impact the fair value estimate. Further, the forfeiture rate impacts the amount of aggregate compensation. These assumptions are subjective and are generally derived from external (such as, risk-free rate of interest) and historical data (such as, volatility factor, expected term and forfeiture rates). Future grants of equity awards accounted for as stock-based compensation could have a material impact on reported expenses depending upon the number, value and vesting period of future awards. The Company issues restricted stock awards in the form of Company common stock. The fair value of these awards is based on the market close price per share on the grant date. The Company expenses the compensation cost of these awards as the restriction period lapses, which is typically a one- to four-year service period to the Company. In fiscal 2018 and 2017, 37,249 and 32,033 shares of common stock were surrendered to the Company to satisfy tax withholding obligations totaling $62,000 and $42,000, respectively, in connection with the vesting of restricted stock awards. Shares surrendered by the restricted stock award recipients in accordance with the applicable plan are deemed canceled, and therefore are not available to be reissued. The Company awarded 501,666 and 220,337 shares of restricted stock to officers and directors of the Company in fiscal 2018 and 2017, respectively.
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and for tax credit and loss carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. In assessing net deferred tax assets, the Company considers whether it is more likely than not that some or all of the deferred tax assets will not be realized. The Company establishes a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. See Note 7 - Income Taxes for further details. The Company provides for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether certain tax positions are more likely than not to be sustained upon examination by tax authorities. At January 31, 2019, the Company believes it has appropriately accounted for any uncertain tax positions. The Company has recorded $275,000 and $295,000 in reserves for uncertain tax positions and corresponding interest and penalties, respectively, as of January 31, 2019 and 2018.
Net Loss Per Common Share	Net Loss Per Common Share The Company presents basic and diluted earnings per share (“EPS”) data for its common stock. Basic EPS is calculated by dividing the net loss attributable to common stockholders of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted EPS is calculated based on the profit or loss attributable to common stockholders and the weighted average number of shares of common stock outstanding adjusted for the effects of all potential dilutive common stock issuances related to options, unvested restricted stock, and convertible preferred stock. Potential common stock dilution related to outstanding stock options and unvested restricted stock is determined using the treasury stock method, while potential common stock dilution related to Series A Convertible Preferred Stock is determined using the “if converted” method. The Company’s unvested restricted stock awards and Series A Convertible Preferred Stock are considered participating securities under ASC 260, Earnings Per Share , which means the security may participate in undistributed earnings with common stock. The Company’s unvested restricted stock awards are considered participating securities because they entitle holders to non-forfeitable rights to dividends or dividend equivalents during the vesting term. The holders of the Series A Convertible Preferred Stock would be entitled to share in dividends, on an as-converted basis, if the holders of common stock were to receive dividends, other than dividends in the form of common stock. In accordance with ASC 260, a company is required to use the two-class method when computing EPS when a company has a security that qualifies as a “participating security.” The two-class method is an earnings allocation formula that determines EPS for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. In determining the amount of net earnings to allocate to common stockholders, earnings are allocated to both common and participating securities based on their respective weighted-average shares outstanding for the period. Diluted EPS for the Company’s common stock is computed using the more dilutive of the two-class method or the if-converted method. In accordance with ASC 260, securities are deemed not to be participating in losses if there is no obligation to fund such losses. For the years ended January 31, 2019 and 2018, the unvested restricted stock awards and the Series A Convertible Preferred Stock were deemed not to be participating since there was a net loss. As of January 31, 2019 and 2018, there were 2,895,464 and 2,949,995 shares of Series A Convertible Preferred Stock outstanding, respectively, each share being convertible into one share of the Company’s common stock. For the years ended January 31, 2019 and 2018, 169,959 and 293,568, respectively, unvested restricted shares of common stock were excluded from the diluted EPS calculation as their effect would have been anti-dilutive. The following is the calculation of the basic and diluted net loss per share of common stock: Fiscal Year 2018 2017 Net earnings (loss) $ (5,865,000) $ (3,099,000) Weighted average shares outstanding - Basic 19,540,980 19,090,899 Stock options, Restricted stock and Series A Convertible Preferred Stock — — Weighted average shares outstanding - Diluted 19,540,980 19,090,899 Basic net earnings (loss) per share of common stock $ (0.30) $ (0.16) Diluted net earnings (loss) per share of common stock $ (0.30) $ (0.16) Diluted net loss per share excludes the effect of stock options as their inclusion would have been anti-dilutive. As of January 31, 2019 and 2018, there were 1,580,657 and 2,173,156 outstanding stock options, respectively.
Loss Contingencies	Loss Contingencies We are subject to the possibility of various loss contingencies arising in the course of business. We consider the likelihood of the loss or impairment of an asset or the incurrence of a liability as well as our ability to reasonably estimate the amount of loss in determining loss contingencies. An estimated loss contingency is accrued when it is probable that a liability has been incurred or an asset has been impaired and the amount of loss can be reasonably estimated. We regularly evaluate current information available to us to determine whether to accrue for a loss contingency and adjust any previous accrual.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the FASB issued ASU 2014‑09, Revenue from Contracts with Customers, Topic 606 (“ASC 606”), which supersedes the revenue recognition requirements in ASC 605, Revenue Recognition. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014‑09 defines a five-step process to achieve this principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. In July 2016, the FASB delayed the effective date by one year and the guidance became effective for us on February 1, 2018. The new revenue recognition guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application as an adjustment to retained earnings (modified retrospective method). We adopted the standard effective February 1, 2018 using the modified retrospective method. We have completed our assessment of our systems, available data and processes affected by the implementation of this new revenue recognition guidance. The Company’s formal accounting policies have been established. As a result of the implementation of this standard, the Company recorded an adjustment to reduce accumulated deficit as of February 1, 2018 by $1.4 million, related primarily to the timing of revenue. The most significant impact relates to our accounting for term software license revenue. Revenues related to SaaS-based offerings, hardware sales, maintenance and support, and audit services remain substantially unchanged. For arrangements which include both software license and maintenance and support components, we expect to recognize the revenue attributed to license upfront at a point in time rather than over the term of the contract. We also expect to recognize license revenues upfront rather than be restricted to payment amounts due under extended payment term contracts as required under the previous guidance. Additionally, the new revenue recognition guidance requires the capitalization of all incremental costs of obtaining a contract with a customer that an entity expects to recover. We had already been capitalizing sales commissions associated with new and renewal contracts. We did not identify any other costs that would be eligible for capitalization under the new guidance. As a result, we did not record any additional deferral for such costs upon adoption of the new guidance on February 1, 2018. In February 2016, the FASB issued ASU 2016‑02, Leases (Topic 842), to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. The ASU is effective for annual periods beginning after December 15, 2018, including interim periods within those fiscal years. The update became effective for us on February 1, 2019. Early adoption of the update is permitted. We currently expect to record right of use assets of approximately $175,000 and additional lease liability of approximately $175,000 upon the adoption of ASU 2016-02. We do not anticipate any material changes to our operating results or liquidity as a result of the adoption of ASU 2016-12. In August 2016, the FASB issued ASU 2016‑15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments , to clarify how certain cash receipts and cash payments should be presented and classified in the statement of cash flows. The ASU should be applied using a retrospective transition method to each period presented. The standard became effective for us on February 1, 2018. The adoption of this ASU did not have a significant impact on our consolidated financial statements. In January 2017, the FASB issued ASU 2017‑01, Business Combinations (Topic 805): Clarifying the Definition of a Business , to clarify the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The standard became effective for us on February 1, 2018. For the periods included in this report, there was no impact on our financial position or results of operations as a result of the adoption of this update. In January 2017, the FASB issued ASU 2017‑04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment , which removes Step 2 from the goodwill impairment test. The standard will be effective for us on February 1, 2020. Early adoption of this update is permitted. We do not expect that the adoption of this ASU will have a significant impact on our consolidated financial statements. In May 2017, the FASB issued ASU 2017‑09, Compensation - Stock Compensation (Topic 718), Scope of Modification Accounting , to clarify which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The update became effective for us on February 1, 2018. For the periods included in this report, there was no impact on our financial position or results of operations as a result of the adoption of this update. In June 2018, the FASB issued ASU 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting , which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The update specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in its own operations by issuing share-based payment awards. ASU 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under ASC 606. The standard is effective for interim and annual periods beginning after December 15, 2018. Early adoption of the update is permitted. We adopted the ASU early effective February 1, 2018. The adoption of this ASU did not have a significant impact on our consolidated financial statements.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Jan. 31, 2019
Significant Accounting Policies
Schedule of Bad Debt Expense	2018 2017 Bad debt expense $ 13,000 $ 234,000
Property and Equipment	Computer equipment and software 3‑4 years Office equipment 5 years Office furniture and fixtures 7 years Leasehold improvements Term of lease or estimated useful life, whichever is shorter
Schedule of Capitalized Software Development Costs	Fiscal Year 2018 2017 Amortization expense on internally-developed software included in: Cost of systems sales $ 768,000 $ 1,914,000 Cost of software as a service 379,000 186,000 Cost of audit services 13,000 13,000 Total amortization expense on internally-developed software $ 1,160,000 $ 2,113,000
Fair Value of Liabilities on a Recurring Basis	Quoted Prices in Significant Other Significant Total Fair Active Markets Observable Inputs Unobservable Inputs Value (Level 1) (Level 2) (Level 3) At January 31, 2019 Royalty liability (1) (3) $ 905,000 $ — $ — $ 905,000 At January 31, 2018 Royalty liability (1) (2) $ 2,469,000 $ — $ — $ 2,469,000 (1) The initial fair value of royalty liability was determined by management with the assistance of an independent third-party valuation specialist, and by management thereafter. Fair value adjustments are included within miscellaneous expense in the consolidated statements of operations. (2) The fair value of the royalty liability was determined based on the probability-weighted revenue scenarios for the Streamline Health® Clinical Analytics solution licensed from Montefiore Medical Center (discussed in Note 12 – Commitments and Contingencies). Following the modification of the Royalty Agreement in the second quarter of fiscal 2018 (discussed in Note 12 – Commitments and Contingencies ), the royalty liability was significantly reduced as a result of the commitment to fulfill a portion of our obligation by providing incremental maintenance services. The fair value of the royalty liability was determined based on the portion of the modified royalty commitment payable in cash.
Schedule of Impact of Adoption of New Accounting Pronouncement	Year Ended January 31, 2019 As reported under Balances without Adjustments due to Revenues Systems sales $ 2,472,000 $ 2,322,000 $ 150,000 Maintenance and support 12,586,000 12,590,000 (4,000) As of January 31, 2019 As reported under Balances without Adjustments due to Assets Contract receivables, current $ 1,263,000 $ 803,000 $ 460,000 Contract receivables, noncurrent 407,000 27,000 380,000 Liabilities Deferred revenues, current 8,338,000 9,084,000 (746,000) Shareholders' Equity Accumulated deficit $ (76,550,000) $ (78,136,000) $ 1,586,000
Schedule of Disaggregated Revenue	Year Ended January 31, 2019 Recurring Revenue Non-recurring Revenue Total Systems sales $ 899,000 $ 1,573,000 $ 2,472,000 Professional services — 1,336,000 1,336,000 Audit services — 1,118,000 1,118,000 Maintenance and support 12,586,000 — 12,586,000 Software as a service 4,853,000 — 4,853,000 Total revenue: $ 18,338,000 $ 4,027,000 $ 22,365,000
Schedule of Cumulative Effect of Adoption of Accounting Pronouncement	As Reported Adjustments As Adjusted ASSETS Contract receivables, current $ 224,000 $ 283,000 $ 507,000 Contract receivables, noncurrent — 468,000 468,000 LIABILITIES Deferred revenues, current 9,482,000 (689,000) 8,793,000 STOCKHOLDERS' EQUITY Accumulated deficit $ (72,125,000) $ 1,440,000 $ (70,685,000)
Schedule of Earnings Per Share, Basic and Diluted	Fiscal Year 2018 2017 Net earnings (loss) $ (5,865,000) $ (3,099,000) Weighted average shares outstanding - Basic 19,540,980 19,090,899 Stock options, Restricted stock and Series A Convertible Preferred Stock — — Weighted average shares outstanding - Diluted 19,540,980 19,090,899 Basic net earnings (loss) per share of common stock $ (0.30) $ (0.16) Diluted net earnings (loss) per share of common stock $ (0.30) $ (0.16)

Debt (Tables)

Debt (Tables)	12 Months Ended
	Jan. 31, 2019
Debt Disclosure [Abstract]
Schedule of Minimum EBITDA Levels	Applicable period Minimum For the fiscal quarter ended October 31, 2018 $ (509,000) For the 2-quarter period ended January 31, 2019 20,000 For the 3-quarter period ending April 30, 2019 204,000 For the 4-quarter period ending July 31, 2019 180,000 For the 4-quarter period ending October 31, 2019 508,000 For the 4-quarter period ending January 31, 2020 408,000 For the 4-quarter period ending April 30, 2020 and each fiscal quarter thereafter 562,000
Summary of Term Loan and Line of Credit	Outstanding principal balances on debt consisted of the following at: January 31, 2019 January 31, 2018 Senior term loan $ 4,030,000 $ 4,626,000 Deferred financing cost (82,000) (128,000) Total 3,948,000 4,498,000 Less: Current portion (597,000) (597,000) Non-current portion of debt $ 3,351,000 $ 3,901,000
Schedule of Future Principal Repayments of Long-Term Debt	Fiscal year Senior Term Loan (1) 2019 $ 597,000 2020 3,433,000 Total repayments $ 4,030,000 Term loan balance on the consolidated balance sheet is reported net of deferred financing costs of $82,000.

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Jan. 31, 2019
Goodwill and Intangible Assets
Schedule of Intangible Assets	January 31, 2019 Estimated Accumulated Useful Life Gross Assets Amortization Net Assets Finite-lived assets: Client relationships 5-10 years $ 5,397,000 $ 3,756,000 $ 1,641,000 Covenants not to compete 3 years 130,000 102,000 28,000 Total $ 5,527,000 $ 3,858,000 $ 1,669,000 January 31, 2018 Estimated Accumulated Useful Life Gross Assets Amortization Net Assets Finite-lived assets: Client relationships 5-15 years 5,805,000 3,308,000 2,497,000 Covenants not to compete 0.5-15 years 986,000 823,000 163,000 Supplier agreements 5 years 1,582,000 1,582,000 — License agreement 15 years 4,431,000 1,256,000 3,175,000 Total $ 12,804,000 $ 6,969,000 $ 5,835,000
Amortization Schedule of Intangible Assets	Annual Amortization Expense 2019 $ 554,000 2020 491,000 2021 455,000 2022 169,000 Total $ 1,669,000

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jan. 31, 2019
Income Taxes
Schedule of Components of Income Tax (Expense) Benefit	Income taxes consist of the following: Fiscal Year 2018 2017 Current tax (expense) benefit: Federal $ 7,000 $ — State (7,000) (11,000) Total current provision — (11,000) Deferred tax benefit: Federal — 95,000 State — — Total deferred tax benefit — 95,000 Current and deferred tax benefit $ — $ 84,000
Schedule of Effective Income Tax Rate Reconciliation	The income tax benefit differs from the amount computed using the federal statutory income tax rates of 21% and 32.9% for fiscal 2018 and 2017, respectively, as follows: Fiscal Year 2018 2017 Federal tax benefit at statutory rate $ (1,232,000) $ 1,047,000 State and local taxes, net of federal benefit (expense) (95,000) 195,000 Change in valuation allowance (767,000) 4,505,000 Permanent items: Incentive stock options 18,000 (112,000) Change in fair value of warrants liability — 15,000 Other 1,000 (24,000) Reserve for uncertain tax position 32,000 (19,000) R&D Credit (Federal) (158,000) 219,000 R&D Credit (State) 134,000 (129,000) Tax Cuts and Jobs Act — (5,827,000) Expiring carryforwards 1,965,000 — Other 102,000 214,000 Income tax benefit $ — $ 84,000
Schedule of Deferred Tax Assets and Liabilities	The income tax effects of these temporary differences and credits are as follows: January 31, 2019 2018 Deferred tax assets: Allowance for doubtful accounts $ 84,000 $ 91,000 Deferred revenue 63,000 155,000 Accruals 141,000 71,000 Net operating loss carryforwards 9,532,000 10,617,000 Stock compensation expense 205,000 236,000 Property and equipment 30,000 109,000 R&D credit 1,102,000 1,144,000 Other 133,000 117,000 Total deferred tax assets 11,290,000 12,540,000 Valuation allowance (11,045,000) (11,813,000) Net deferred tax assets 245,000 727,000 Deferred tax liabilities: Finite-lived intangible assets (245,000) (727,000) Total deferred tax liabilities (245,000) (727,000) Net deferred tax liabilities $ — $ —
Schedule of Gross Unrecognized Tax Benefits	2018 2017 Beginning of fiscal year $ 295,000 $ 290,000 Additions for tax positions for the current year 32,000 62,000 Additions for tax positions of prior years — 3,000 Subtractions for tax positions of prior years (52,000) (60,000) End of fiscal year $ 275,000 $ 295,000

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Jan. 31, 2019
Stock-Based Compensation
Schedule of Stock Option Activity	A summary of stock option activity follows: Weighted Average Remaining Aggregate Options Exercise Price Life in Years intrinsic value Outstanding as of February 1, 2018 2,173,156 $ 3.42 Granted 47,000 1.68 Exercised (50,694) 1.18 Expired (201,469) 2.55 Forfeited (387,336) 3.61 Outstanding as of January 31, 2019 1,580,657 $ 3.50 6.13 $ 15,000 Exercisable as of January 31, 2019 1,401,435 $ 3.73 5.91 $ 8,000 Vested or expected to vest as of January 31, 2019 1,542,516 $ 3.54 6.09 $ 14,000 (1) The exercise prices range from $1.10 to $8.10, of which 440,000 shares are between $1.10 and $2.00 per share, 362,240 shares are between $2.19 and $4.00 per share, and 778,417 shares are between $4.02 and $8.10 per share. (2) The exercise prices range from $1.18 to $8.10, of which 280,778 shares are between $1.18 and $2.00 per share, 362,240 shares are between $2.19 and $4.00 per share, and 758,417 shares are between $4.02 and $8.10 per share.
Schedule of Weighted-Average Assumptions	The fiscal 2018 and 2017 stock-based compensation was estimated at the date of grant using a Black-Scholes option pricing model with the following weighted average assumptions for each fiscal year: 2018 2017 Expected life 6 years 6 years Risk-free interest rate 2.89 % 2.65 % Weighted average volatility factor 0.65 0.65 Dividend yield — — Forfeiture rate 20 % 13 %
Schedule of Restricted Stock Award Activity	A summary of restricted stock award activity for fiscal 2018 and 2017 is presented below: Weighted Non-vested Average Number of Grant Date Shares Fair Value Non-vested balance at January 31, 2017 858,225 $ 1.59 Granted 295,337 1.17 Vested (331,975) 1.47 Forfeited — — Non-vested balance at January 31, 2018 821,587 $ 1.59 Granted 826,666 1.15 Vested (453,537) 1.34 Forfeited (130,850) 1.61 Non-vested balance at January 31, 2019 1,063,866 $ 1.27

Organization and Description _2

Organization and Description of Business (Details) - segment	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Organization and Description of Business
Number of operating segments	1	1

Significant Accounting Polici_4

Significant Accounting Policies - Additional Information (Details) - USD ($)	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Allowance for Doubtful Accounts
Allowance for doubtful accounts	$ 345,000	$ 349,000
Bad debt expense	13,000	234,000
Concessions Accrual
Concessions Costs	$ 44,000	$ 48,000

Significant Accounting Polici_5

Significant Accounting Policies - Property, Plant, and Equipment (Details)	Dec. 13, 2013	Jan. 31, 2019USD ($)	Jan. 31, 2018USD ($)	Jan. 31, 2015
Property, Plant and Equipment
Depreciation expense		$ 450,000	$ 774,000
Leases
Area under lease (sq. ft.)	24,335			10,350
Duration of rent allowance	8 months			2 months
Computer equipment and software | Minimum
Property, Plant and Equipment
Property, plant and equipment, useful life		3 years
Computer equipment and software | Maximum
Property, Plant and Equipment
Property, plant and equipment, useful life		4 years
Office equipment
Property, Plant and Equipment
Property, plant and equipment, useful life		5 years
Office furniture and fixtures
Property, Plant and Equipment
Property, plant and equipment, useful life		7 years

Significant Accounting Polici_6

Significant Accounting Policies - Capitalized Software Development Costs (Details) - USD ($)	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Capitalized Software Development Costs
Capitalized computer software, additions	$ 3,003,000	$ 1,836,000
Cost of systems sales	768,000	1,914,000
Cost of software as a service	379,000	186,000
Cost of audit services	13,000	13,000
Total amortization expense on internally-developed software	1,160,000	2,113,000
Research and development expense	$ 4,261,000	$ 5,352,000
Minimum
Capitalized Software Development Costs
Useful life of capitalized computer software	3 years
Maximum
Capitalized Software Development Costs
Useful life of capitalized computer software	5 years

Significant Accounting Polici_7

Significant Accounting Policies - Fair Value of Liabilities (Details) - USD ($)	Jan. 31, 2019	Jan. 31, 2018
Fair Value, Liabilities Measured on Recurring Basis
Royalty liability	$ 905,000	$ 2,469,000
Significant Unobservable Inputs (Level 3)
Fair Value, Liabilities Measured on Recurring Basis
Royalty liability	$ 905,000	$ 2,469,000

Significant Accounting Polici_8

Significant Accounting Policies - Software as a Service (Details) - USD ($)	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Revenue Recognition
Deferred professional costs	$ 251,000	$ 471,000
Accumulated amortization of deferred costs	399,000	312,000
Amortization of professional expenses	$ 346,000	$ 270,000

Significant Accounting Polici_9

Significant Accounting Policies - Impact on the Financial Statements from Adoption of New Accounting Standard (Details) - USD ($)	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	Feb. 01, 2018
Revenues
Professional services	$ 1,336,000	$ 2,744,000
Audit services	1,118,000	1,216,000
Software as a service	4,853,000	5,864,000
Total revenues	22,365,000	24,338,000
Revenue recognized	9,449,000
Assets
Contract receivables, current	1,263,000	224,000	$ 507,000
Contract receivables, noncurrent	407,000		468,000
Liabilities
Deferred revenues, current	8,338,000	9,482,000	8,793,000
Stockholders’ equity
Accumulated deficit	(76,550,000)	(72,125,000)	$ (70,685,000)
Recurring Revenue
Revenues
Software as a service	4,853,000
Total revenues	18,338,000
Non-recurring Revenue
Revenues
Professional services	1,336,000
Audit services	1,118,000
Total revenues	4,027,000
System Sales
Revenues
Revenues	2,472,000	1,343,000
System Sales | Recurring Revenue
Revenues
Revenues	899,000
System Sales | Non-recurring Revenue
Revenues
Revenues	1,573,000
Maintenance and Support
Revenues
Revenues	12,586,000	13,171,000
Maintenance and Support | Recurring Revenue
Revenues
Revenues	12,586,000
Balances without adoption of ASC 606
Assets
Contract receivables, current	803,000
Contract receivables, noncurrent	27,000
Liabilities
Deferred revenues, current	9,084,000
Stockholders’ equity
Accumulated deficit	(78,136,000)
Balances without adoption of ASC 606 | System Sales
Revenues
Revenues	2,322,000
Balances without adoption of ASC 606 | Maintenance and Support
Revenues
Revenues	12,590,000
Adjustments due to ASC 606
Assets
Contract receivables, current	460,000	283,000
Contract receivables, noncurrent	380,000	468,000
Liabilities
Deferred revenues, current	(746,000)	(689,000)
Stockholders’ equity
Accumulated deficit	1,586,000	$ 1,440,000
Adjustments due to ASC 606 | System Sales
Revenues
Revenues	150,000
Adjustments due to ASC 606 | Maintenance and Support
Revenues
Revenues	$ (4,000)

Significant Accounting Polic_10

Significant Accounting Policies - Revenue Performance Obligations (Details) $ in Millions	12 Months Ended
	Jan. 31, 2019USD ($)
Significant Accounting Policies
Revenue, Remaining Performance Obligation	$ 27
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-02-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Percentage of remaining performance obligation to be recognized over the next 12 months	65.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	12 months

Significant Accounting Polic_11

Significant Accounting Policies - Contract Acquisition Costs (Details) - USD ($)	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Capitalized Contract Costs, Net
Capitalized contract costs, amortization	$ 145,000
Prepaid Assets
Capitalized Contract Costs, Net
Capitalized contract costs, net	185,000	$ 136,000
Other Current Assets
Capitalized Contract Costs, Net
Capitalized contract costs, net	$ 114,000	$ 116,000

Significant Accounting Polic_12

Significant Accounting Policies - Other (Details)	Dec. 13, 2013	Jan. 31, 2019USD ($)segmentshares	Jan. 31, 2018USD ($)segmentshares	Jan. 31, 2015	Feb. 01, 2019USD ($)	Feb. 01, 2018USD ($)
Allowance for Doubtful Accounts
Allowance for doubtful accounts		$ 345,000	$ 349,000
Bad debt expense		13,000	234,000
Concessions Accrual
Concessions Costs		44,000	48,000
Leases
Area under lease (sq. ft.)	24,335			10,350
Duration of rent allowance	8 months			2 months
Capitalized Software Development Costs
Capitalized computer software, additions		3,003,000	1,836,000
Capitalized computer software, amortization		1,160,000	2,113,000
Research and development expense		$ 4,261,000	$ 5,352,000
Goodwill and Intangible Assets
Number of operating segments | segment		1	1
Number of reportable segments | segment		1
Equity Awards
Share-based compensation expense		$ 629,000	$ 1,109,000
Income Taxes
Reserves for uncertain tax positions and corresponding interest and penalties		$ 275,000	$ 295,000
Net Earnings (Loss) Per Common Share
Preferred stock to common stock conversion ratio		1
New Accounting Pronouncements and Changes in Accounting Principles
Cumulative impact of new accounting principle		$ 1,440,000
Convertible Preferred Stock
Net Earnings (Loss) Per Common Share
Antidilutive securities (in shares) | shares		2,895,464	2,949,995
Stock Options
Net Earnings (Loss) Per Common Share
Antidilutive securities (in shares) | shares		1,580,657	2,173,156
Minimum
Capitalized Software Development Costs
Useful life of capitalized computer software		3 years
Maximum
Capitalized Software Development Costs
Useful life of capitalized computer software		5 years
Restricted Stock
Equity Awards
Shares surrendered for tax withholding (in shares) | shares		37,249	32,033
Tax withholding obligations		$ 62,000	$ 42,000
Shares awarded (in shares) | shares		501,666	220,337
Restricted Stock | Minimum
Equity Awards
Required service period		1 year
Restricted Stock | Maximum
Equity Awards
Required service period		4 years
Internally-developed software | Minimum
Goodwill and Intangible Assets
Estimated useful life		1 year
Internally-developed software | Maximum
Goodwill and Intangible Assets
Estimated useful life		10 years
ASU 2016-02
Leases
Right of use assets					$ 175,000
Additional lease liability					$ 175,000
Retained Earnings
New Accounting Pronouncements and Changes in Accounting Principles
Cumulative impact of new accounting principle		$ 1,440,000
Retained Earnings | ASU 2014-09
New Accounting Pronouncements and Changes in Accounting Principles
Cumulative impact of new accounting principle						$ 1,400,000

Significant Accounting Polic_13

Significant Accounting Policies - Earnings Per Share (Details) - USD ($)	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Significant Accounting Policies
Net earnings (loss)	$ (5,865,000)	$ (3,099,000)
Weighted average shares outstanding - Basic (in shares)	19,540,980	19,090,899
Weighted average shares outstanding - Diluted (in shares)	19,540,980	19,090,899
Basic net earnings (loss) per common stock (in dollars per share)	$ (0.30)	$ (0.16)
Diluted net earnings (loss) per common stock (in dollars per share)	$ (0.30)	$ (0.16)

Preferred Stock - Series A Conv

Preferred Stock - Series A Convertible Preferred Stock Narrative (Details) - USD ($)	Nov. 01, 2012	Jan. 31, 2019	Jan. 31, 2018	Aug. 16, 2012
Class of Stock [Line Items]
Shares converted (in shares)		54,531
Amount converted		$ 164,000
Series A Preferred Stock
Class of Stock [Line Items]
Shares converted (in shares)		54,531
Amount converted		$ 164,000
Convertible redeemable preferred stock, shares outstanding (in shares)		2,895,464	2,949,995
Private Placement | Series A Preferred Stock
Class of Stock [Line Items]
New issuance of series A convertible preferred stock (in shares)				2,416,785
Preferred stock, par value (in USD per share)				$ 3
Period over which share price is evaluated		10 days
Share price (in USD per share)		$ 8
Period over which trade volume is evaluated		60 days
Average daily trading volume for period (in shares)		100,000
Stock price at time of conversion (in USD per share)		$ 3
Common shares issued for convertible note and accrued interest (in shares)	1,583,210

Operating Leases (Details)

Operating Leases (Details) - USD ($)	3 Months Ended		12 Months Ended
	Oct. 31, 2018	Jul. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Loss on exit of operating lease			$ 1,034,000
Rent and leasing expense			964,000	$ 1,234,000
NEW YORK
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Total due			478,000
Loss on exit of operating lease		$ 472,000
Total sublease rentals to be received		384,000	$ 216,000
Loss on disposal of fixed assets		$ (48,000)
GEORGIA
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Loss on exit of operating lease	$ 562,000
Broker commissions	275,000
Loss on disposal of fixed assets	499,000
Loss on write-off of lease incentive liability	$ 239,000

Debt - Narrative (Details)

Debt - Narrative (Details) - USD ($)	Apr. 15, 2015	Jan. 31, 2019	Jan. 31, 2018	Nov. 21, 2014
Debt Instrument [Line Items]
Payment of principal		$ 597,000	$ 1,112,000
Senior Notes
Debt Instrument [Line Items]
Deferred finance costs		82,000	$ 128,000
Revolving Credit Facility
Debt Instrument [Line Items]
Commitment fee in connection with the term loan		14,000
Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Revolving line of credit		5,000,000		$ 5,000,000
Borrowings outstanding		0
Credit Agreement | Senior Notes
Debt Instrument [Line Items]
Revolving line of credit				$ 10,000,000
Minimum | LIBOR | Credit Agreement
Debt Instrument [Line Items]
Basis spread on interest rate (as a percent)	4.25%
Minimum | Base Rate | Credit Agreement
Debt Instrument [Line Items]
Basis spread on interest rate (as a percent)	3.25%
Maximum | LIBOR | Credit Agreement
Debt Instrument [Line Items]
Basis spread on interest rate (as a percent)	6.25%
Maximum | Base Rate | Credit Agreement
Debt Instrument [Line Items]
Basis spread on interest rate (as a percent)	5.25%
January 31, 2018
Debt Instrument [Line Items]
Minimum liquidity		5,000,000
February 1, 2018 through January 31, 2019
Debt Instrument [Line Items]
Minimum liquidity		4,000,000
February 1, 2019
Debt Instrument [Line Items]
Minimum liquidity		3,500,000
February 1, 2019 and Later
Debt Instrument [Line Items]
Minimum liquidity		$ 4,000,000

Debt - Minimum EBITDA Levels (D

Debt - Minimum EBITDA Levels (Details) - Credit Agreement	12 Months Ended
	Jan. 31, 2019USD ($)
July 31, 2017
Debt Instrument [Line Items]
Minimum EBITDA level	$ (509,000)
October 31, 2017
Debt Instrument [Line Items]
Minimum EBITDA level	20,000
January 31, 2018
Debt Instrument [Line Items]
Minimum EBITDA level	204,000
April 30, 2018
Debt Instrument [Line Items]
Minimum EBITDA level	180,000
July 31, 2018
Debt Instrument [Line Items]
Minimum EBITDA level	508,000
October 31, 2018
Debt Instrument [Line Items]
Minimum EBITDA level	408,000
January 31, 2019
Debt Instrument [Line Items]
Minimum EBITDA level	$ 562,000

Debt - Outstanding Principal Ba

Debt - Outstanding Principal Balances (Details) - USD ($)	Jan. 31, 2019	Jan. 31, 2018
Debt Instrument [Line Items]
Less: Current portion	$ 597,000	$ 597,000
Senior Notes
Debt Instrument [Line Items]
Senior term loan	4,030,000	4,626,000
Deferred financing cost	(82,000)	(128,000)
Long-term Debt	3,948,000	4,498,000
Less: Current portion	597,000	597,000
Non-current portion of debt	$ 3,351,000	$ 3,901,000

Debt - Schedule of Future Princ

Debt - Schedule of Future Principal Repayments of Long-Term Debt (Details) - Senior Notes - USD ($)	Jan. 31, 2019	Jan. 31, 2018
Debt Instrument [Line Items]
2019	$ 597,000
2020	3,433,000
Total repayments	4,030,000	$ 4,626,000
Deferred finance costs	$ 82,000	$ 128,000

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Intangibles (Details) - USD ($)	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Intangible Assets, Net (Including Goodwill) [Abstract]
Gross Assets	$ 5,527,000	$ 12,804,000
Accumulated Amortization	3,858,000	6,969,000
Net Assets	1,669,000	5,835,000
Impairment of long-lived assets	3,681,000
Client relationships
Intangible Assets, Net (Including Goodwill) [Abstract]
Gross Assets	5,397,000	5,805,000
Accumulated Amortization	3,756,000	3,308,000
Net Assets	$ 1,641,000	$ 2,497,000
Client relationships | Minimum
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	5 years	5 years
Client relationships | Maximum
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	10 years	15 years
Covenants not to compete
Intangible Assets, Net (Including Goodwill) [Abstract]
Gross Assets	$ 130,000	$ 986,000
Accumulated Amortization	102,000	823,000
Net Assets	$ 28,000	$ 163,000
Covenants not to compete | Minimum
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life	3 years	6 months
Covenants not to compete | Maximum
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life		15 years
Supplier agreements
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life		5 years
Gross Assets		$ 1,582,000
Accumulated Amortization		$ 1,582,000
License agreement
Intangible Assets, Net (Including Goodwill) [Abstract]
Estimated Useful Life		15 years
Gross Assets		$ 4,431,000
Accumulated Amortization		1,256,000
Net Assets		$ 3,175,000

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Schedule of Future Amortization Expense (Details) - USD ($)	Jan. 31, 2019	Jan. 31, 2018
Goodwill and Intangible Assets
2019	$ 554,000
2020	491,000
2021	455,000
2022	169,000
Net Assets	$ 1,669,000	$ 5,835,000

Income Taxes - Components of In

Income Taxes - Components of Income Tax Expense (Details) - USD ($)	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Current tax (expense) benefit:
Federal	$ 7,000
State	$ (7,000)	$ (11,000)
Total current provision		(11,000)
Deferred tax benefit:
Federal		95,000
Total Deferred tax benefit		95,000
Income tax benefit		$ 84,000

Income Taxes - Tax Provision at

Income Taxes - Tax Provision at Statutory Rate Reconciliation (Details) - USD ($)	Jan. 01, 2018	Dec. 22, 2017	Jan. 31, 2019	Jan. 31, 2018
Income Tax Contingency [Line Items]
Statutory income tax rate	21.00%	34.00%	21.00%	32.90%
Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]
Federal tax benefit at statutory rate of 32.9 percent			$ (1,232,000)	$ 1,047,000
State and local taxes, net of federal benefit (expense)			(95,000)	195,000
Change in valuation allowance			(767,000)	4,505,000
Incentive stock options			18,000	(112,000)
Change in fair value of warrants liability				15,000
Other			1,000	(24,000)
Reserve for uncertain tax position			32,000	(19,000)
Tax Cuts and Jobs Act				(5,827,000)
Expiring carryforwards			1,965,000
Other			102,000	214,000
Income tax benefit				84,000
Federal
Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]
R&D Credit			(158,000)	219,000
State
Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]
R&D Credit			$ 134,000	$ (129,000)

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Tax Carryforwards (Details) - USD ($)	Jan. 31, 2019	Jan. 31, 2018
Deferred tax assets:
Allowance for doubtful accounts	$ 84,000	$ 91,000
Deferred revenue	63,000	155,000
Accruals	141,000	71,000
Net operating loss carryforwards	9,532,000	10,617,000
Stock compensation expense	205,000	236,000
Property and equipment	30,000	109,000
R&D credit	1,102,000	1,144,000
Other	133,000	117,000
Total deferred tax assets	11,290,000	12,540,000
Valuation allowance	(11,045,000)	(11,813,000)
Net deferred tax assets	245,000	727,000
Deferred tax liabilities:
Definite-lived intangible assets	(245,000)	(727,000)
Total deferred tax liabilities	$ (245,000)	$ (727,000)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Income Tax Contingency [Line Items]
Operating loss carryforwards, not subject to expiration	$ 3,900,000
Valuation allowance	11,045,000	$ 11,813,000
Change in valuation allowance	(767,000)	4,505,000
Reserves for uncertain tax positions and corresponding interest and penalties	275,000	295,000
Accrued interest and penalties	0	$ 0
Internal Revenue Service (IRS)
Income Tax Contingency [Line Items]
Operating loss carryforwards	36,800,000
Change in valuation allowance	768,000
State
Income Tax Contingency [Line Items]
Operating loss carryforwards, subject to expire next twenty fiscal years	$ 17,170,000

Income Taxes - Unrecognized Tax

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Beginning of fiscal year	$ 295,000	$ 290,000
Additions for tax positions for the current year	32,000	62,000
Additions for tax positions of prior years		3,000
Subtractions for tax positions of prior years	(52,000)	(60,000)
End of fiscal year	$ 275,000	$ 295,000

Income Taxes - Tax Cuts and Job

Income Taxes - Tax Cuts and Jobs Act (Details) - USD ($)	Jan. 01, 2018	Dec. 22, 2017	Jan. 31, 2019	Jan. 31, 2018
Income Taxes
Statutory income tax rate	21.00%	34.00%	21.00%	32.90%
Tax Cuts and Jobs Act				$ (5,827,000)

Major Clients - (Details)

Major Clients - (Details) - Customer Concentration Risk - item	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Total Revenues | Customer One
Concentration Risk
Number of customers	0	0
Accounts Receivable | Customer One
Concentration Risk
Concentration risk, percentage	12.00%	12.00%
Accounts Receivable | Customer Two
Concentration Risk
Concentration risk, percentage	9.00%	11.00%

Employee Retirement Plan (Detai

Employee Retirement Plan (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2019	Dec. 31, 2018	Jan. 31, 2018
Employee Retirement Plan
Matching contribution percent (up to)	50.00%		100.00%
Maximum contribution as a percent of participant compensation	4.00%		4.00%
Defined contribution plan, cost recognized		$ 483,000		$ 524,000

Employee Stock Purchase Plan (D

Employee Stock Purchase Plan (Details) - USD ($)	Jun. 30, 2019	Jan. 02, 2019	Jan. 31, 2019	Jan. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award
Closing price		$ 0.88
$0.98 per share
Share-based Compensation Arrangement by Share-based Payment Award
Closing price			$ 1.10
$0.91 per share
Share-based Compensation Arrangement by Share-based Payment Award
Closing price			1.10
$1.02 per share
Share-based Compensation Arrangement by Share-based Payment Award
Closing price			$ 2.19
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award
Number of shares authorized to be purchased under Employee Stock Purchase Plan (in shares)			1,000,000
Employee Stock Purchase Plan, maximum annual contribution per employee, percent			10.00%
Employee Stock Purchase Plan, percent of fair market value, prior year			85.00%
Employee Stock Purchase Plan, percent of fair market value, current year			85.00%
Shares remaining available for grant (in shares)			431,556
Allocated share-based compensation expense			$ 4,000	$ 19,000
Cash received from purchase of shares under Employee Stock Purchase Plan			$ 22,000	$ 45,000
Employee Stock Purchase Plan | $0.69 per share
Share-based Compensation Arrangement by Share-based Payment Award
Stock purchased during period, shares, Employee Stock Purchase Plan (in shares)			13,339
Stock purchased during period, price per share, Employee Stock Purchase Plan (in USD per share)			$ 0.69
Employee Stock Purchase Plan | $1.20 per share
Share-based Compensation Arrangement by Share-based Payment Award
Stock purchased during period, shares, Employee Stock Purchase Plan (in shares)			10,370
Stock purchased during period, price per share, Employee Stock Purchase Plan (in USD per share)			$ 1.20
Employee Stock Purchase Plan | $0.98 per share
Share-based Compensation Arrangement by Share-based Payment Award
Stock purchased during period, shares, Employee Stock Purchase Plan (in shares)				21,234
Stock purchased during period, price per share, Employee Stock Purchase Plan (in USD per share)				$ 0.98
Employee Stock Purchase Plan | $0.91 per share
Share-based Compensation Arrangement by Share-based Payment Award
Stock purchased during period, shares, Employee Stock Purchase Plan (in shares)				26,048
Stock purchased during period, price per share, Employee Stock Purchase Plan (in USD per share)				$ 0.91
Scenario, Forecast | Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award
Purchase price discount	85.00%

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details)	Jan. 02, 2019$ / shares	Jan. 31, 2019USD ($)$ / sharesshares	Jan. 31, 2018USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award
Options outstanding		1,580,657	2,173,156
Options issued (in shares)		47,000
Options expired (in shares)		201,469
Options forfeited (in shares)		387,336
Options exercised (in shares)		50,694
Exercise price range, lower range limit (in USD per share) | $ / shares	$ 0.88
Options exercisable (in shares)		1,401,435
Weighted average grant date fair value (in USD per share) | $ / shares		$ 1.03	$ 0.65
Total intrinsic value | $		$ 13,000	$ 0
Compensation cost not yet recognized | $		$ 98,000
Weighted average period of recognition for compensation cost		7 months 6 days
Cash received from the exercise of options | $		$ 0	0
Change in control percentage		20
$0.98 per share
Share-based Compensation Arrangement by Share-based Payment Award
Exercise price range, lower range limit (in USD per share) | $ / shares		$ 1.10
Exercise price range, upper range limit (in USD per share) | $ / shares		$ 8.10
$0.91 per share
Share-based Compensation Arrangement by Share-based Payment Award
Options outstanding		440,000
Exercise price range, lower range limit (in USD per share) | $ / shares		$ 1.10
Exercise price range, upper range limit (in USD per share) | $ / shares		$ 2
$1.02 per share
Share-based Compensation Arrangement by Share-based Payment Award
Options outstanding		362,240
Exercise price range, lower range limit (in USD per share) | $ / shares		$ 2.19
Exercise price range, upper range limit (in USD per share) | $ / shares		$ 4
Options exercisable (in shares)		362,240
$4.02 to $8.10
Share-based Compensation Arrangement by Share-based Payment Award
Options outstanding		778,417
Exercise price range, lower range limit (in USD per share) | $ / shares		$ 4.02
Exercise price range, upper range limit (in USD per share) | $ / shares		$ 8.10
Options exercisable (in shares)		758,417
$1.18 to $8.10
Share-based Compensation Arrangement by Share-based Payment Award
Exercise price range, lower range limit (in USD per share) | $ / shares		$ 1.18
Exercise price range, upper range limit (in USD per share) | $ / shares		8.10
$1.18 to $2.00
Share-based Compensation Arrangement by Share-based Payment Award
Exercise price range, lower range limit (in USD per share) | $ / shares		1.18
Exercise price range, upper range limit (in USD per share) | $ / shares		$ 2
Options exercisable (in shares)		280,778
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award
Allocated share-based compensation expense | $		$ 244,000	563,000
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award
Weighted average period of recognition for compensation cost		2 years 3 months 18 days
Allocated share-based compensation expense | $		$ 383,000	$ 546,000
Compensation cost not yet recognized | $		$ 1,110,000
2013 Incentive Compensation Plan | Blended Equity Awards (Stock Options, Stock Appreciation Rights, Resticted Stock)
Share-based Compensation Arrangement by Share-based Payment Award
Shares authorized to issue		2,300,000
Term of options granted (or less)		10 years
Vesting period		3 years
Options outstanding		1,355,657	1,873,156
2013 Incentive Compensation Plan | SAR's
Share-based Compensation Arrangement by Share-based Payment Award
SAR's outstanding (in shares)		0
Executive Inducement Grants | Stock Options
Share-based Compensation Arrangement by Share-based Payment Award
Options outstanding		225,000	300,000
Options issued (in shares)		0	0
Options expired (in shares)		0	0
Options forfeited (in shares)		75,000	0
Options exercised (in shares)		0	0
Minimum | 2013 Incentive Compensation Plan | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period		1 year
Maximum | 2013 Incentive Compensation Plan | Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period		4 years

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details)	12 Months Ended
	Jan. 31, 2019USD ($)$ / sharesshares
Options
Outstanding - beginning of year (in shares) | shares	2,173,156
Granted (in shares) | shares	47,000
Exercised (in shares) | shares	(50,694)
Expired (in shares) | shares	(201,469)
Forfeited (in shares) | shares	(387,336)
Outstanding - end of year (in shares) | shares	1,580,657
Options exercisable (in shares) | shares	1,401,435
Vested or expected to vest - end of year (in shares) | shares	1,542,516
Weighted Average Exercise Price
Outstanding - beginning of year (USD per share) | $ / shares	$ 3.42
Granted (USD per share) | $ / shares	1.68
Exercised (USD per share) | $ / shares	1.18
Expired (USD per share) | $ / shares	2.55
Forfeited (USD per share) | $ / shares	3.61
Outstanding - end of year (USD per share) | $ / shares	3.50
Weighted Average Exercise Price, Exercisable - end of year (USD per share) | $ / shares	3.73
Weighted Average Exercise Price, Vested or expected to vest - end of year (USD per share) | $ / shares	$ 3.54
Remaining Life in Years, Outstanding	6 years 1 month 17 days
Remaining Life in Years, Exercisable	5 years 10 months 28 days
Remaining Life in Years, Vested or expected to vest	6 years 1 month 2 days
Aggregate intrinsic value of outstanding options at year end | $	$ 15,000
Aggregate intrinsic value of exercisable options at year end | $	8,000
Aggregate intrinsic value of options vested or expected to vest at year end | $	$ 14,000

Stock-Based Compensation - Weig

Stock-Based Compensation - Weighted Average Assumptions (Details) - USD ($)	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Stock-Based Compensation
Expected life	6 years	6 years
Risk-free interest rate	2.89%	2.65%
Weighted average volatility factor	65.00%	65.00%
Dividend yield	$ 0	$ 0
Forfeiture rate	20.00%	13.00%

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Restricted Stock Award Activity (Details) - Restricted Stock - $ / shares	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Non-vested Number of Shares
Non-vested number of shares, beginning of period (in shares)	821,587	858,225
Granted (in shares)	826,666	295,337
Vested (in shares)	(453,537)	(331,975)
Forfeited (in shares)	(130,850)	0
Non-vested number of shares, end of period (in shares)	1,063,866	821,587
Weighted Average Grant Date Fair Value
Non-vested at beginning of period (USD per share)	$ 1.59	$ 1.59
Granted (USD per share)	1.15	1.17
Vested (USD per share)	1.34	1.47
Forfeited (USD per share)	1.61	0
Non-vested at end of period (USD per share)	$ 1.27	$ 1.59

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($)	Jul. 01, 2018	Oct. 25, 2013	Jan. 31, 2019	Jan. 31, 2018
Commitments and Contingencies
Minimum fees due under shared office arrangement			$ 286,000
Royalty liability			905,000	$ 2,469,000
Royalty Agreement with Montefiore
Commitments and Contingencies
Term of licensing agreement		15 years
One-time initial base royalty fee		$ 3,000,000
Minimum commitment for additional royalty payments		$ 3,000,000
Period of time over which additional royalty payments are to be made	6 years 6 months
Term of maintenance and service	24 months
Cash payment due per royalty agreement	$ 1,000,000
Deferred revenue			$ 1,172,000

Schedule II - Valuation and Q_2

Schedule II - Valuation and Qualifying Accounts and Reserves (Details) - USD ($)	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	$ 349,000
Charged to Costs and Expenses	(126,000)	$ (95,000)
Balance at End of Period	345,000	349,000
Allowance for doubtful accounts
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	349,000	198,000
Charged to Costs and Expenses	13,000	234,000
Deductions	(17,000)	(83,000)
Balance at End of Period	$ 345,000	$ 349,000